US20010018601A1 - Temperature sensing devices and methods to shrink tissues - Google Patents

Temperature sensing devices and methods to shrink tissues Download PDF

Info

Publication number
US20010018601A1
US20010018601A1 US09/170,765 US17076598A US2001018601A1 US 20010018601 A1 US20010018601 A1 US 20010018601A1 US 17076598 A US17076598 A US 17076598A US 2001018601 A1 US2001018601 A1 US 2001018601A1
Authority
US
United States
Prior art keywords
tissue
component
temperature
probe
heat transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/170,765
Other versions
US6322584B2 (en
Inventor
Frank W. Ingle
Loren L. Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astora Womens Health LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US09/170,765 priority Critical patent/US6322584B2/en
Application filed by Individual filed Critical Individual
Assigned to SURX, INC. reassignment SURX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: INGLE, FRANK W., ROY, LOREN L.
Priority to AU51225/99A priority patent/AU5122599A/en
Priority to PCT/US1999/016597 priority patent/WO2000006061A1/en
Assigned to COMDISCO, INC., MMC/GATX PARTNERSHIP NO.1 reassignment COMDISCO, INC. SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SURX, INC.
Publication of US20010018601A1 publication Critical patent/US20010018601A1/en
Publication of US6322584B2 publication Critical patent/US6322584B2/en
Application granted granted Critical
Assigned to MMC/GATX PARTNERSHIP NO. I reassignment MMC/GATX PARTNERSHIP NO. I RELEASE OF SECURITY INTEREST FILED ON 8/16/99 Assignors: SURX, INC.
Assigned to SURX, INC. reassignment SURX, INC. TERMINATION SECURITY INTEREST IN PATENTS Assignors: COMDISCO, INC., MMC/GATX PARTNERSHIP NO. I
Assigned to SOLARANT MEDICAL, INC. reassignment SOLARANT MEDICAL, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SURX, INC.
Assigned to AMS RESEARCH CORPORATION reassignment AMS RESEARCH CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SOLARANT MEDICAL, INC.
Assigned to CIT HEALTHCARE LLC reassignment CIT HEALTHCARE LLC SECURITY AGREEMENT Assignors: SOLARANT MEDICAL, INC.
Assigned to SOLARANT MEDICAL, INC. reassignment SOLARANT MEDICAL, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CIT HEALTHCARE LLC
Assigned to MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT reassignment MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT SECURITY AGREEMENT Assignors: AMS RESEARCH CORPORATION
Assigned to AMS RESEARCH CORPORATION reassignment AMS RESEARCH CORPORATION RELEASE OF PATENT SECURITY INTEREST Assignors: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Assigned to DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT reassignment DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT GRANT OF SECURITY INTEREST IN PATENTS Assignors: AMERICAN MEDICAL SYSTEMS, INC., AMS RESEARCH CORPORATION, ENDO PHARMACEUTICALS SOLUTIONS, INC., ENDO PHARMACEUTICALS, INC., LASERSCOPE
Assigned to LASERSCOPE, AMS RESEARCH, LLC, AMERICAN MEDICAL SYSTEMS, LLC reassignment LASERSCOPE RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: DEUTSCHE BANK AG NEW YORK BRANCH
Assigned to AMS RESEARCH, LLC reassignment AMS RESEARCH, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: AMS RESEARCH CORPATION
Assigned to APHRODITE WOMEN'S HEALTH, LLC reassignment APHRODITE WOMEN'S HEALTH, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMS RESEARCH, LLC
Assigned to ASTORA WOMEN'S HEALTH, LLC reassignment ASTORA WOMEN'S HEALTH, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: APHRODITE WOMEN'S HEALTH, LLC
Assigned to AMS RESEARCH, LLC reassignment AMS RESEARCH, LLC CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED AT REEL: 037300 FRAME: 0318. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Assignors: AMS RESEARCH CORPORATION
Assigned to WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE reassignment WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASTORA WOMEN'S HEALTH, LLC
Anticipated expiration legal-status Critical
Assigned to GENERICS BIDCO I, LLC, ENDO PHARMACEUTICALS INC., ACTIENT PHARMACEUTICALS LLC, ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.), AUXILIUM US HOLDINGS, LLC, BIOSPECIFICS TECHNOLOGIES CORP., DAVA INTERNATIONAL, LLC, PAR PHARMACEUTICAL, INC., VINTAGE PHARMACEUTICALS, LLC, QUARTZ SPECIALTY PHARMACEUTICALS, LLC, ASTORA WOMEN’S HEALTH HOLDINGS, LLC, PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC), SLATE PHARMACEUTICALS, LLC, DAVA PHARMACEUTICALS, LLC, ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.), GENERICS INTERNATIONAL (US), INC., ASTORA WOMEN’S HEALTH LLC, AUXILIUM PHARMACEUTICALS, LLC, BIOSPECIFICS TECHNOLOGIES LLC reassignment GENERICS BIDCO I, LLC RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: WILMINGTON TRUST, NATIONAL ASSOCIATION
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B18/1482Probes or electrodes therefor having a long rigid shaft for accessing the inner body transcutaneously in minimal invasive surgery, e.g. laparoscopy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B18/1402Probes for open surgery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/08Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by means of electrically-heated probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/1206Generators therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00005Cooling or heating of the probe or tissue immediately surrounding the probe
    • A61B2018/00011Cooling or heating of the probe or tissue immediately surrounding the probe with fluids
    • A61B2018/00023Cooling or heating of the probe or tissue immediately surrounding the probe with fluids closed, i.e. without wound contact by the fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00005Cooling or heating of the probe or tissue immediately surrounding the probe
    • A61B2018/00047Cooling or heating of the probe or tissue immediately surrounding the probe using Peltier effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053Mechanical features of the instrument of device
    • A61B2018/0016Energy applicators arranged in a two- or three dimensional array
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00505Urinary tract
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00553Sphincter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00696Controlled or regulated parameters
    • A61B2018/00702Power or energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00696Controlled or regulated parameters
    • A61B2018/00726Duty cycle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00696Controlled or regulated parameters
    • A61B2018/00761Duration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00791Temperature
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00875Resistance or impedance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/1206Generators therefor
    • A61B2018/124Generators therefor switching the output to different electrodes, e.g. sequentially
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/1206Generators therefor
    • A61B2018/1246Generators therefor characterised by the output polarity
    • A61B2018/1253Generators therefor characterised by the output polarity monopolar
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/1206Generators therefor
    • A61B2018/1246Generators therefor characterised by the output polarity
    • A61B2018/126Generators therefor characterised by the output polarity bipolar
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/1815Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves
    • A61B2018/1861Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves with an instrument inserted into a body lumen or cavity, e.g. a catheter

Definitions

  • the present invention generally relates to medical devices, methods and systems for selectively contracting tissues, particularly for the treatment of urinary incontinence.
  • Urinary incontinence arises in both men and women with varying degrees of severity, and from different causes.
  • men the condition most frequently occurs as a result of prostatectomies which result in mechanical damage to the urethral sphincter.
  • women the condition typically arises after pregnancy when musculoskeletal damage has occurred as a result of inelastic stretching of the structures which support the genitourinary tract.
  • pregnancy can result in inelastic stretching of the pelvic floor, the external sphincter, and the tissue structures which support the bladder and bladder neck region.
  • urinary leakage typically occurs when a patient's abdominal pressure increases as a result of stress, e.g., coughing, sneezing, laughing, exercise, or the like.
  • Treatment of urinary incontinence can take a variety of forms. Most simply, the patient can wear absorptive devices or clothing, which is often sufficient for minor leakage events. Alternatively or additionally, patients may undertake exercises intended to strengthen the muscles in the pelvic region, or may attempt a behavior modification intended to reduce the incidence of urinary leakage.
  • the present invention provides improved devices, methods, and systems for repeatably and reliably contracting fascia and other support tissues, particularly for the treatment of urinary incontinence.
  • the techniques of the present invention generally enhance the support provided by the natural tissues of the pelvic floor.
  • the present invention Rather than relying entirely on the surgeon's ability to observe, direct, and control the selective shrinking of these tissues, the present invention generally makes use of tissue contraction systems which are placed statically against the target tissue, and which direct sufficient energy into the tissue so as to inhibit incontinence or the like.
  • the treatment surface will often engage a relatively large area of the endopelvic fascia, and will be held in a static position against this tissue. While the electrodes are energized under computer control the device heats and shrinks the engaged endopelvic fascia with minimal collateral damage to the surrounding fascia and tissues, while the device structure and controller will together generally avoid ablation of the engaged endopelvic fascia.
  • the present invention can take advantage of automated energy delivery circuits and/or selectable contraction probes having treatment surfaces of a variety of selectable sizes and shapes so as to predictably contract the target tissue, rather than relying entirely on a surgeon's skill to contract the proper amount of tissue, for example, by manually “painting” a small electrode along the tissue surface, and may also reduce fouling along the electrode/tissue interface.
  • the invention provides a device for therapeutically heating a target tissue of a patient body.
  • the device comprises a probe body having a heat transfer surface oriented for engaging a target tissue.
  • a component is thermally coupled to the heat transfer surface.
  • the component has an electrical characteristic which varies predictably with temperature.
  • a conductor is electrically coupled to the component.
  • the heat transfer surface can be used to both heat the tissue and to thermally couple a component to the target tissue so as to provide a tissue temperature signal.
  • the component which typically comprises a transistor or diode, can also be used as a resistive heater.
  • the diode can be used in a heating/temperature indicating circuit by alternatively applying a relatively high electrical power across the diode to heat the tissue, and then applying a relatively low power to the diode to measure the forward junction voltage of the diode. As the voltage across a transistor or diode often varies by about 2.0 mV/° C., the low power measurement will permit calculation of the tissue temperature.
  • the invention provides a tissue contraction system comprising a heat transfer surface oriented for engaging a tissue surface of a tissue.
  • An electrical component is thermally coupled to the heat transfer surface, and a power supply is electrically coupled to the component. Electrical energy from the power supply heats the component, and the component heats the tissue to a tissue contraction temperature by thermal conduction through the heat transfer surface and the tissue surface.
  • FIG. 1 is a lateral cross-sectional view showing the urinary bladder and a bladder support structure.
  • FIG. 2 is a cross-sectional view of a patient suffering from urinary stress incontinence due to inelastic stretching of the endopelvic fascia.
  • FIG. 3 shows a known method for treating urinary incontinence by affixing sutures around the bladder neck.
  • FIG. 4 illustrates improved bladder support provided by contracting the endopelvic fascia according to the principles of the present invention.
  • FIG. 5 is a perspective view of a probe having a thin flat credit card shaped body and a treatment surface with a two-dimensional array of bi-polar electrode pairs.
  • FIG. 5A is a front view of the probe of FIG. 5.
  • FIGS. 5B and C are side and front views, respectively, of a probe having an electrode array supported by a shaft.
  • FIGS. 5 D-G illustrate the structure and electrical layout of the electrode array for the probe of FIGS. 5A and B.
  • FIGS. 6 A-C are schematic block diagram showings of a static tissue contraction system having an electrode array with optional temperature feedback signals.
  • FIGS. 7 A-E schematically illustrate methods for accessing left and right target regions of the endopelvic fascia.
  • FIG. 8 is a cross-sectional view showing a method for treating a left target region of the endopelvic fascia.
  • FIGS. 9 A-D schematically illustrate a picture frame shaped tissue contraction device having an independently energizeable peripheral portion so as to treat tissue surrounding an initially contracted region.
  • FIGS. 10A and B illustrate an alternative probe having a two-dimensional electrode array.
  • FIGS. 11A and B illustrate a probe structure having a two-dimensional array of posts for independently engaging, heating and contracting tissue, in which the posts may optionally include resistive heaters and temperature sensors.
  • FIG. 12 is a cross-sectional view of a probe structure having heat transfer surfaces thermally coupled to diodes and to the target tissue so as to allow the diodes to act as both heaters and temperature sensors.
  • FIG. 12A is a drive/feedback block diagram for the probe of FIG. 12.
  • FIG. 13 illustrates an alternative probe structure in which a conduit directs a heated fluid along a treatment surface of the probe.
  • FIG. 14 illustrates a still further alternative probe in which a plurality of irrigation ports are disposed between a one-dimensional array of elongate electrodes.
  • FIG. 15 illustrates a semi-rigid probe body which flexes to help ensure the treatment surface of the probe is in contact with the target tissue.
  • FIG. 16 illustrates a probe having a cavity that receives the urethra to help ensure that the treatment surface is separated from the urethra by a protection zone.
  • FIGS. 17 A-C illustrate front and side views of a probe having a balloon which urges the treatment surface of the probe against the target tissue.
  • FIGS. 18 A-C illustrate a minimally invasive probe having interspersed heating and cooling areas to effect tissue contraction with minimal damage to the target tissue, and in which the probe includes a balloon that can be inserted to a treatment site in a narrow configuration and expanded at the treatment site to engage and treat the full target region without moving the probe.
  • FIGS. 19 A-C illustrate a probe having interspersed hot and cold posts.
  • FIG. 20 is a cross-sectional view showing a probe having a heating element with a limited quantity of a reaction material such that the total heat energy that will be transmitted to the target tissue is limited.
  • FIG. 21 illustrates a tissue contracting kit including the probe of FIG. 5 and instructions for its use.
  • the present invention generally provides methods, devices, and systems which repeatably contract tissue, particularly as a therapy for incontinence.
  • the techniques of the invention will generally involve positioning a probe so that a surface of the probe engages a target tissue statically, that is, without relative movement between the probe and the engaged tissue surface during treatment. Energy will then be transmitted from the treatment surface of the probe into the target tissue so as to effect the desired contraction. This allows the contraction to be controlled by the configuration and/or software of the system, rather than relying on a surgeon's experience to allow him or her to “paint” a small area electrode surface across a sufficient portion of the target region at a proper rate to effect contraction without imposing excessive injury on the target tissue.
  • the techniques of the present invention will often be used to contract fascia, tendons, and other collagenous tissues, preferably without ablation of these collagenous tissues.
  • Collagenous tissues may occasionally be referred to herein as collagenated tissues.
  • endopelvic fascia EF defines a hammock-like structure which extends laterally between the left and right arcus tendinous fascia pelvis ATFP. These later structures extend substantially between the anterior and posterior portions of the pelvis, so that the endopelvic fascia EF largely defines the pelvic floor.
  • the fascial tissue of the pelvic floor may comprise tissues referred to under different names by surgeons of different disciplines, and possibly even by different practitioners within a specialty.
  • some surgeons may assign the collagenous support structure referred to herein as the endopelvic fascia one name when viewed from a superior approach, and a different name when viewed from an inferior approach.
  • Some or all of this support structure may comprise two collagenous layers with a thin muscular layer therebetween, or may comprise a single collagenous layer.
  • the therapy of the present invention may be directed toward any of the collagenous portions of the support structures for the urethra, bladder neck, and bladder.
  • the treated tissues may include and/or be referred to as endopelvic fascia, arcus tendinous fascia pelvis, urethropelvic ligaments, periurethral fascia, levator fascia, vesicopelvic fascia, transversalis fascia, and/or vesicle fascia, as well as other collagenous support structures.
  • the bladder In women with urinary stress incontinence due to bladder neck hypermobility, the bladder has typically dropped between about 1.0 cm and 1.5 cm (or more) below its nominal position. This condition is typically due to weakening and/or stretching of the pelvic support tissues, including the endopelvic fascia, the arcus tendinous fascia pelvis, and the surrounding ligaments and muscles, often as a result of bearing children.
  • the present invention generally provides a therapy which effectively reduces the length of the pelvic support tissues and returns bladder B towards its nominal position.
  • the bladder is still supported by the fascia, muscles, ligaments, and tendons of the natural pelvic support tissues.
  • bladder B can be seen to have dropped from its nominal position (shown in phantom by outline 10 ). While endopelvic fascia EF still supports bladder B to maintain continence when the patient is at rest, a momentary pressure pulse P opens the bladder neck N resulting in a release of urine through urethra UR.
  • a known treatment for urinary stress incontinence relies on suture S to hold bladder neck N closed so as to prevent inadvertent voiding, as seen in FIG. 3.
  • Suture S may be attached to bone anchors affixed to the pubic bone, ligaments higher in the pelvic region, or the like. In any case, loose sutures provide insufficient support of bladder neck N and fail to overcome urinary stress incontinence. Over tightening suture S may make normal urination difficult and/or impossible.
  • bladder B may be elevated from its lowered position (shown by lowered outline 12 ).
  • contraction of selected tissues may reduce or eliminate slack in the support structures without raising the bladder, and/or may reduce the elongation of the support structures to reduce dropping of the bladder when under stress.
  • a pressure pulse P will then be resisted in part by endopelvic fascia EF which supports the lower portion of the bladder, helping maintain the bladder neck in a closed configuration.
  • Fine tuning of the support provided by the endopelvic fascia is possible through selective modification of the anterior portion of the endopelvic fascia.
  • To close the bladder neck and raise bladder B upward for example, it may be possible to effect a greater total tissue contraction towards the front.
  • repositioning of bladder B to a more forward position may be affected by selectively contracting the dorsal portion of the endopelvic fascia EF to a greater extent then the forward portion.
  • the therapy of the present invention may be tailored to the particular weakening exhibited by a patient's pelvic support structures. Regardless, the portion of the endopelvic fascia EF adjacent the bladder neck and urethra UR can remain free of sutures or other artificial support structures which might directly compress the urethra.
  • a credit card shaped probe 20 includes a thin flat probe body 22 having a treatment surface 24 .
  • a two-dimensional array of electrodes 26 is distributed across treatment surface 24 , the electrodes here being arranged in bipolar pairs.
  • Conductors 28 here in the form of a plurality of insulated wires jacketed in a single bundle, extend from probe body 22 for coupling an electrical energy source to electrodes 26 .
  • treatment surface 24 of probe 20 has a length 29 and a width 30 that are significantly greater than a thickness of probe body 22 .
  • Length 24 will typically be at least about 10 mm, while width 30 will generally be at least about 5 mm.
  • length 28 will be between about 10 and 50 mm, with width 30 being between about 5 and 30 mm.
  • Probe body 22 will usually have a thickness of between about 1 and 15 mm. In many embodiments, the thickness of probe body 22 will be about 8 mm or less, typically being from about 8 mm to about 1 mm, and preferably being about 5 mm or less.
  • the probe body will often be at least semi-rigid. In other words, although probe body 22 may flex, the probe body will generally have a stiffness greater than that of fascial tissue. This helps ensure that each of electrodes 26 can be effectively coupled to the fascial tissue surface by urging an interior portion of the probe body against the target tissue. Body 22 may flex slightly during such pressure so that both surfaces conform somewhat to each other. Body 22 may be substantially rigid so that the fascial surface conforms substantially entirely to the shape of probe 20 .
  • the probe body may comprise a polymer such as polycarbonate, ABS plastic, or the like.
  • the tissue temperature can be controlled in a variety of ways so as to limit variability in efficacy.
  • Feedback to a computer which controls power to electrodes 26 might directly indicate temperature, or the computer might instead control the treatment time.
  • Signals might be provided to the computer indicating the electrical power being used, the electrical energy which has been input to the tissue, or the impedance of the tissue as measured by the current and voltage of the RF energy delivered to the probe.
  • the spacing between treated and non-treated regions may be set by the structure of the probe and array, and/or by selectively energizing the electrodes of the probe. This further controls the therapy to eliminate or reduce user variability.
  • Electrodes 26 may be substantially flush with tissue treatment surface 24 , or may alternatively protrude from the tissue treatment surface. When protruding electrodes are used, they will often present a rounded surface for engagement against the fascial tissue so as to minimize the concentration of electrical current density (as might otherwise occur at sharp corners). As is explained in more detail in U.S. patent application Ser. No. 08/910,370, filed Aug. 13, 1997, the full disclosure of which is incorporated herein by reference, the depth of tissue treatment may be varied when using bi-polar electrodes by setting the spacing 32 between a pair of electrodes 34 , and/or by setting a diameter or radius of curvature of electrodes 26 where they engage the tissue surface.
  • the electrodes have a radius of curvature of 0.012 inches, are formed of stainless steel, and are separated by about six times the radius of curvature (between their inner edges) to limit heating depth to less than about 3 mm.
  • the spacing between electrode pairs should allow treatment of a relatively large amount of fascia without damage to the urethra. Spacing between pairs may also leave some untreated tissue interspersed between the treated regions, which will promote healing.
  • the interspersed untreated areas of the target tissue may comprise fascia and/or other collagenous tissues, and the pairs may be separated such that at least a portion of the untreated tissue can remain at or below a maximum safe tissue temperature throughout treatment, optionally remaining below 60° C., and in some embodiments remaining below 45° C.
  • a fascial tissue can be safely heated to a contraction temperature by transmitting a current between a pair of electrodes having a radius of curvature at the tissue interface in a range from about 0.05 to about 2.0 mm, ideally being about 0.3 mm, where the electrodes are separated by a distance in the range from about 1 to about 10 times the radius of curvature of the electrodes.
  • the driving energy may be applied using an intermittent duty cycle to effect the desired increase in temperature.
  • the tissue will be heated to a safe contraction temperature in a range from about 70° C. to about 140° C. for a time in the range from about 0.5 to about 40 secs, typically for a time from about 0.5 to about 10 secs.
  • FIGS. 5B and C An alternative probe structure 20 ′ is illustrated in FIGS. 5B and C.
  • probe body 22 is supported by a rigid shaft 23 extending from a handle 25 .
  • Shaft 23 may be bent to orient treatment surface 24 to engage the endopelvic fascia.
  • a flex joint 27 may be provided at the junction of shaft 23 and probe body 22 to help ensure that the entire treatment surface 24 engages the fascial surface when the treatment surface is held in position manually from handle 25 .
  • Joint 27 may comprise a pliable or resilient structure and/or material adjacent the shaft/body interface, such as an elastomer, a polymer, a ball and socket arrangement, a pair of orthogonal pivots, or the like.
  • Shaft 23 may comprise a stainless steel hypotube containing the conductors coupled to electrodes 26 , or any of a variety of alternative metal, polymer, or composite structures.
  • the handle will often comprise a polymer such as polycarbonate, ABS plastic, or the like, and may optionally include controls for energizing the electrodes.
  • the configuration of the electrode array is generally fixed by the probe body structure. This often sets the tissue heating pattern (based on the electrode size and spacing between electrode pairs), as the probe body will be held at a fixed position against the tissue during tissue heating. This predetermined heating pattern helps avoid over-treatment of some tissues and under contraction of others, as can occur when manually painting a small treatment surface repeatedly across the target tissue.
  • the shape and layout of the electrodes can provide preferential contraction of the target tissue along a desired orientation.
  • the engaged tissue can be contracted to a significantly greater extent in width (across the electrode pairs) than in length (along the electrodes).
  • any pattern of elongate heated tissue zones (such as between an elongate pair of electrodes) may provide preferential contraction across the elongate heat zones as compared to along their length, particularly when such elongate heat zones are alternated with elongate untreated zones (such as between the pairs). This can be extremely useful when a surgeon wants to, for example, decrease a lateral width of the endopelvic fascia while minimizing the reduction in its anterior/posterior length.
  • Probe body 22 will often be formed as a multilayer structure to facilitate electrically coupling conductors 28 to electrodes 26 . As shown in FIG. 5, for monopolar operation, only a single conductor need be electrically coupled to the electrodes, while a separate conductor can be coupled to a large return electrode placed on the leg or back of the patient. Bipolar operation will generally include at least two-conductors, while both monopolar and bipolar probes will often include larger numbers of conductors to selectively vary the electrical power across treatment surface 24 .
  • Electrodes 26 are formed from wires of stainless steel, copper, or the like, but may alternatively comprise plates oriented perpendicularly to the treatment surface, the plates having rounded or radiused edges, with only the edges exposed. Electrodes 26 are coupled to the power supply with wires or other conductors disposed between a main probe body 22 a and a back insulating layer 22 b.
  • the conductors extend proximally through hypotube 23 , which may also include a lumen for delivering a conduction enhancing liquid or gel, typically for delivery of about 1 cc/min of saline through one or more weep holes in treatment surface 24 adjacent or between the pairs of electrodes (as can be understood with reference to FIG. 14).
  • Probe body 22 will typically be rigid in this embodiment, often being formed of a polymer such as ABS plastic, polycarbonate, or the like, but may alternatively be semi-rigid (typically comprising silicone or nylon).
  • Probe 20 may optionally include a variety of mechanisms to actively control contraction of the target tissue.
  • body 22 may include multiplexing circuitry which selectively directs electrical energy supplied through a limited number of conductors to the electrodes or electrode pairs. Such circuitry will optionally vary the electrical energy or duty cycle of the electrodes depending on temperatures measured at or near the electrodes. Alternatively, a uniform heating energy may be directed from treatment surface 24 based on one or more temperature measurements, based on dosimetry, or the like. Circuitry for probe 20 may incorporate microprocessors or the like. Alternatively, signals may be transmitted from the probe to an external processor for control of the contraction energy.
  • FIGS. 5F and G Exemplary probe circuits are illustrated in FIGS. 5F and G.
  • the coupling arrangement illustrated in FIG. 5F allows an M ⁇ N array of electrode pairs to be selectably energized using only M+N conductors. This arrangement takes advantage of the fact that current (and heating) will be concentrated along the path of least electrical resistance, which will generally be between the two closest bipolar electrodes.
  • rows of electrodes are coupled together and columns of electrodes are coupled together so that a particular electrode pair 1 , 2 , 3 , . . . 6 is selected by driving a current between the associated column and the associated row.
  • electrode pair 3 is selected by driving bipolar current between the electrodes of column 1 and the electrodes of row 2 .
  • the electrode pairs are energized by heating each pair associated with a column starting with the middle pair (for example, pair 3 , then pair 1 , then pair 5 ), and then moving on to the next column (for example, pair 4 , pair 2 , and then pair 6 ).
  • Temperature sensors 31 may comprise thermistors, thermocouples, or the like, and will be mounted to probe body 22 so as to engage the tissue between a pair of electrodes to limit the number of signal wires, temperature sensors 31 are coupled to a multiplexer MUX mounted in handle 25 , or possibly in probe body 22 .
  • temperature sensors provide temperature signals which are repeatable (for each mounted sensor) though not necessarily predictable, the accuracy of the temperature feedback can be enhanced by storing calibration data for this probe, and ideally for each temperature sensor, in a non-volatile memory such as an EEPROM.
  • FIGS. 6 A-C Static contraction systems including probe 20 are shown schematically in FIGS. 6 A-C.
  • power from an electrical power source 33 is directed to the electrodes of probe 20 ′ by a switching unit 35 under the direction of a processor 37 .
  • These functions may be combined in a variety of arrangements, such as by including the processor and the switching unit, some or all of the switching unit circuitry with the probe, or the like.
  • temperature feedback is provided, such as in the system of FIG. 6C, the temperature may be controlled by selectively energizing and halting power to the probe (sometimes called a bang-bang feedback control) to maintain the desired temperature or temperature profile, or the controller and/or switching unit may selectively vary the power level.
  • the total desired shrinkage of a discrete target region of endopelvic fascia EF may be controlled without moving probe 20 .
  • Total contraction of the endopelvic fascia will depend on a number of factors. Generally, tissue will contract locally by up to 70% (areal shrinkage) when heated to a contraction temperature range. Therefore, it is possible to select a probe 20 having a treatment surface 24 with a size and shape suitable for providing a total effective contraction of endopelvic fascia EF so as to provide the desired improvement in support of the pelvic floor. It may therefore be desirable to provide a series of differing probes for contracting tissues by differing amounts.
  • a probe having a lateral dimension of 12 mm may be selected to decrease an effective lateral dimension of the right portion of the endopelvic fascia by 5 mm.
  • a greater amount of contraction might be effected by selecting an alternate probe with a greater width.
  • Selecting probes having differing lengths, selecting among alternative probes having treatment surfaces 24 which are wider at one end than the other, or selectively positioning the probe along the midline might allow the surgeon to tailor the enhanced support to lift the anterior or posterior portions of the bladder to a greater or lesser degree, as desired.
  • Still further alternative contraction control mechanisms might be used. Rather than selecting alternative probes, it may be possible to vary the heating energy among the electrodes. Where a lesser degree of contraction is desired, the surgeon may heat the tissue to a lower temperature, and/or may selectively heat only a portion of the tissue which engages treatment surface 24 (for example, by energizing only a selected subset of electrodes 26 ). Electrical properties of the system can be monitored before, during, between, and/or after energizing the probe with tissue heating current. For example, as the controller selectively energizes the electrode pairs, the system impedance can be monitored to help ensure that sufficient electrode/tissue coupling is maintained for the desired treatment.
  • a warning light may illuminate to inform the surgeon that coupling was (or is) insufficient.
  • More sophisticated feedback systems may re-treat selected undertreated areas by re-energizing electrode pairs for which coupling was compromised.
  • these feedback systems generate a feedback signal FS to indicate an effect of the treatment on the tissue, as schematically illustrated in FIG. 6A.
  • Feedback signal FS may simply provide an indication to the surgeon, or may be processed by the controller to modify the treatment. Regardless, this controlled contraction can be provided without moving probe 20 .
  • endopelvic fascia EF can be viewed as left and right fascial portions separated at the patient's midline by urethra UR. Endopelvic fascia EF is supported by ligaments ATFP above a vaginal wall VW. It may be desirable to selectively shrink endopelvic fascia EF along target regions 40 which extend in an anterior posterior direction along the left and right sides of the endopelvic fascia. This should provide enhanced support of urethra UR, the bladder neck, and the bladder with little risk of heating, denervating or injuring the delicate urethral tissues.
  • a weighted speculum 42 is inserted into the vagina to expose the anterior vaginal wall VW.
  • elongated laterally offset incisions 43 might be made in the anterior vaginal wall so that the vaginal mucosa could be manually dissected to reveal the endopelvic fascia EF.
  • a small incision 44 may be made on either side of urethra UR, thereby allowing access for a minimally invasive blunt dissection device 46 .
  • Dissection device 46 includes a mechanical expansion element in the form of a balloon 48 at its distal end.
  • Balloon 48 dissects the back side of the vaginal wall from the endopelvic fascia to create a minimally invasive treatment site 50 along each of the discrete target regions 40 , as seen in FIG. 7D.
  • the exposed endopelvic fascia will preferably be irrigated with saline or the like to reduce fouling of the electrodes, and to enhance electrode/tissue coupling with a conductive film.
  • the patient will preferably be positioned so that excess irrigation fluid drains from the tissue surface, and aspiration will often be provided to clear any drained fluids.
  • FIG. 7E An alternative method for accessing the endopelvic fascia is illustrated in FIG. 7E.
  • This is sometimes referred to as the Raz technique, and generally comprises separating an arch-shaped mid-line flap F from the surrounding vaginal wall VW to access the underlying and adjacent endopelvic fascia as shown. This procedure was described in more detail by Shlomo Raz in Female Urology, 2nd. Ed. (1996) on pages 395-397.
  • probe 20 is inserted through incisions 43 or 44 to treatment site 50 .
  • Treatment surface 24 is urged against exposed surface 52 of endopelvic fascia EF so that electrodes 26 are effectively coupled with the endopelvic fascia.
  • Probe 20 may be biased against the endopelvic fascia manually by pressing against the wall of vaginal mucosa VM, by pressing directly against the probe using a finger inserted through incision 43 or 44 , or using a shaft attached to the probe that extends proximally through the incision.
  • probe 20 may include a mechanical expansion mechanism for urging treatment surface 24 against the endopelvic fascia EF.
  • Electrodes 26 are energized via conductors 28 (see FIG. 5). Electrodes 26 direct electrical current through the endopelvic fascia so that the resistance of the fascia causes an increase in tissue temperature.
  • the use of relatively large electrode surfaces having a sufficiently large radius of curvature avoids excessive concentration of electrical current density near the tissue/electrode interface which might cause charring, tissue necrosis, or excessive injury to the tissue.
  • endopelvic fascia EF As endopelvic fascia EF is heated by probe 20 , the collagenated tissues within the fascia contract, drawing the tissue inward along treatment surface 24 . Although probe 20 does not move during this contraction, it should be noted that at least a portion of endopelvic fascia EF may slide along treatment surface 24 , since the tissue contracts while the probe generally does not.
  • FIG. 9A schematically illustrates a treatment surface 24 having a peripheral “picture frame” portion 56 which can be energized independently of an interior portion 54 .
  • tissue 58 engaging treatment surface 24 contracts inward as shown in FIG. 9B.
  • peripheral portion 56 can be energized independently of the interior portion so that the uncontracted tissue 60 that now engages treatment surface 24 can be safely contracted.
  • interior portions 54 and peripheral portion 56 are illustrated as contiguous treatment zones, it should be understood that they may actually comprise independently energizeable arrays of electrodes. Additionally, it should be understood that peripheral portion 56 need not completely surround interior portion 54 , particularly where the probe includes some structure that affixes a portion of the probe relative to the engaged tissue.
  • electrodes 62 may optionally comprise monopolar or bipolar rounded buttons or flat disks defining a two-dimensional array.
  • a temperature sensor may be provided for each button.
  • radiofrequency current may be driven from one button electrode to another.
  • radiofrequency current may be driven from each button to a large surface area pad applied against the patient's back in a monopolar configuration.
  • radiofrequency current When used in a bipolar mode, it may be desirable to drive radiofrequency current between pairs of electrodes that are separated by at least one other electrode. This may allow heating to a more even depth, as heating energy will be concentrated near the engaged tissue surface adjacent each electrode, but will be distributed to a greater depth midway between the electrodes of a bipolar pair. For example, it is possible to drive radiofrequency current from electrode 62 a to electrode 62 c, from electrode 62 b to electrode 62 d, from electrode 62 e to electrode 62 g, from electrode 62 f to electrode 62 h, and the like.
  • buttons electrodes of FIGS. 10A and B may be mounted on an inflatable balloon which could be rolled up into a narrow configuration for insertion to the treatment site. The balloon could then be inflated to allow engagement of the treatment surface against the target tissue.
  • FIGS. 11A and B A still further alternative probe structure is illustrated in FIGS. 11A and B.
  • a two-dimensional array of protrusions 64 each include a resistive heater 66 and a temperature sensor 68 .
  • the ends of protrusions 64 can safely include corners without concentrating heat.
  • the protrusions can have heat transfer ends that are round, square, hexagonal, or the like, and the protrusions can be cylindrical, conical, or some other desired shape.
  • flush heat transfer surfaces may be formed with similar structures.
  • the protrusions 64 can be pressed against the tissue surface and resistive heaters 66 can be energized while active temperature feedback is provided by temperature sensor 68 .
  • This feedback can be used to heat the protrusions to the desired treatment temperature for a predetermined time so as to effect the desired tissue contraction.
  • the temperature sensors may measure the actual temperature of the tissue, rather than that of the protrusion.
  • a two-dimensional array of heat transfer surfaces 70 might make use of thermally conductive materials that extend from or are flush with treatment surface 24 .
  • At least one electrical component 72 is thermally coupled to an associated heat transfer surface 70 so that the component varies in temperature with the temperature of the surface.
  • the component will typically have an electrical characteristic which varies with temperature, the component typically comprising a transistor, thermistor, or silicon diode.
  • Component 72 can be coupled to conductor 28 using a printed circuit board 74 .
  • Electrical current is driven through component 72 so that the component heats heat transfer surface 70 .
  • the tissue engaging heat transfer surface 24 is heated by passive conduction from heat transfer surfaces 70 .
  • the heating electrical current is applied as intermittent pulses. Between heating pulses, a small constant current can be driven through a diode in a forward direction, and the voltage across the junction can be measured using printed circuit board 74 .
  • the forward voltage across this junction is often dependent on the temperature of the junction, typically varying by about 2 mv/° C. for a silicon diode. This forward voltage can be used to measure the junction temperature.
  • the timing of the heating pulses and the structure of heat transfer surface 70 can be set so that the diode junction will indicate the temperature of the tissue against which the heat transfer surface is engaged, with the diode junction preferably being at or near an equilibrium temperature during a slow gradual heat cycle.
  • the temperature indication signal provided by the low-power, between heating pulse can be used as a feedback control signal.
  • the array ideally comprises a two-dimensional array, and feedback signals from multiple heat transfer surfaces of the array should allow very good control of the local tissue contraction temperature throughout the treatment surface/tissue interface.
  • Such an array of transistors or diodes coupled to a power source via conductor 28 and printed circuit board 74 provides a very inexpensive way to selectively control the temperature across treatment surface 24 .
  • FIG. 12A is an exemplary circuit including the probe of FIG. 12.
  • a large variable current I 1 is sufficient to heat diodes 72 so as to treat the engaged tissue, preferably under proportional control.
  • a small constant current I 2 does not significantly heat the engaged tissue, but does allow measurement of the forward voltage drop across each diode. Applying a constant small current I 2 , the voltage drop across a diode 72 thermally coupled (through a metal plate) to the tissue will be about 0.7 v - 2 mV/° C. for a silicon diode so as to indicate the tissue temperature.
  • an EEPROM or other non-volatile memory may store calibration data for each diode, ideally storing calibration for constants at lest two temperatures from calibration tests conducted prior to delivery and/or use of the probe.
  • FIGS. 13 and 14 still further alternative heating mechanisms might be used.
  • a conduit 76 directs a relatively high temperature fluid along a serpentine path adjacent treatment surface 74 , the heated fluid typically comprising steam or the like.
  • a one dimensional array of elongate electrodes 80 is distributed across treatment surface 24 , with irrigation ports 82 being disposed between and/or around the electrodes.
  • the midline need not be dissected, as described above. This minimizes the possibility of inadvertently treating and/or injuring the urethra.
  • treatment can be made symmetric by statically positioning the probe against the target region on the left side of the endopelvic fascia, and statically positioning the same or a different probe on the right side of the endopelvic fascia without accessing the fascia adjacent the urethra.
  • probe body 22 can be understood with reference to FIG. 15.
  • Probe 20 flexes when held against endopelvic fascia EF by a force F to ensure engagement between treatment surface 24 and the endopelvic fascia throughout the desired interface region.
  • probe body 22 may be pre-curved to facilitate coupling between the treatment surface and the target tissue.
  • a thin flat probe body which is slightly convex might be held against the target tissue by pressure F 2 at the edges of the treatment surface (rather than a central pressure F) until the device becomes substantially flat, thereby indicating to the surgeon that the proper amount of tissue engaging pressure is being applied.
  • FIG. 16 illustrates a structure and method for aligning probe body 22 along the endopelvic fascia so that treatment region 40 is separated from the urethra by a protection zone 86 .
  • a catheter 88 is introduced into the urethra, which facilitates identification of the urethra along the endopelvic fascia.
  • cooled water may be circulated through the catheter to avoid any injury to the urethra during treatment. It should be understood that such a urethral cooling system may be desirable for many embodiments of the present systems and methods.
  • urethra UR is received in a cavity 88 of probe body 22 .
  • Cavity 88 is separated from treatment surface 24 by a desired protection zone 86 .
  • the probe body may extend bilaterally on both sides of the urethra to simultaneously treat the left and right portions of the endopelvic fascia, as is indicated by the dashed outline 90 .
  • Such a bilateral system can avoid injury to the urethral tissues by heating two (left and right) discrete treatment regions separated by a protection zone.
  • Bilateral systems might evenly treat the two sides of the endopelvic fascia by sequentially energizing two separated arrays of electrodes in a mirror-image sequence, the two sides being treated simultaneously, sequentially, or in an alternating arrangement.
  • the static tissue contraction probes of the present invention may optionally include an expansion mechanism such as balloon 92 to urge treatment surface 24 against the target tissue.
  • the device might again be inserted through incisions into the anterior vaginal wall on either side of the urethra.
  • Electrodes 26 are again mounted on a probe body 22 which is at least semi-rigid, with a resilient balloon 92 molded to the back of the probe body.
  • the balloon can be inflated after the probe is positioned to urge treatment surface 24 against the target tissue with a repeatable electrode/fascia interface pressure.
  • Balloon 92 will preferably comprise an elastomer such as silicone or the like.
  • defibrillator gel or saline may be provided at the treatment surface/tissue interface. These enhanced coupling materials may be placed on the probe or tissue surface prior to engagement therebetween, or may alternatively be delivered through ports adjacent the electrodes.
  • FIGS. 18 A-C illustrate a still further alternative probe structure.
  • an expandable probe 94 is inserted through a small incision while the probe is in a narrow configuration.
  • balloon 96 is inflated via an inflation lumen 98 .
  • the balloon expands against an opposing tissue so as to urge treatment surface 24 against the endopelvic fascia.
  • a hot fluid conduit 100 is arranged in a serpentine pattern which alternates with a cold fluid conduit 102 so that the treatment surface comprises interspersed zones of heating and cooling. Heating tissues to a safe contraction temperature between cooled zones will induce contraction with less injury to the tissue than would otherwise be imposed, as the regions of heated tissue are interspersed with, and protected by, the tissue cooling.
  • FIGS. 19 A-C Still further alternative treatment mechanisms are illustrated in FIGS. 19 A-C, and in FIG. 20.
  • tissue heating and cooling are interspersed using a device which includes a heated plate 104 having a series of heated protrusions 106 in combination with a cooled plate 108 having interspersed cooled protrusions 110 and passages 112 .
  • Passages 112 receive heated protrusions 106
  • a thermally insulating material 114 insulates the plates surrounding the protrusions from each other and the target tissue.
  • This device may optionally make use of active resistive heating of the entire hot plate 104 , in some cases with temperature feedback provided from a single temperature sensor.
  • hot plate 104 will preferably be thick enough so that heat transfer through the plate from protrusion to protrusion is sufficient so that the temperature gradient from one protrusion to another is negligible, allowing uniform treatment across the treatment surface.
  • protrusions 106 may not be actively heated while in contact with the target tissue. Instead, hot plate 104 may be heated prior to contact with the tissue so that heat transfer to the tissue is provided by the heat capacity of hot plate 104 , as predetermined from the specific heat of the hot plate material, the quantity of hot plate material, and the like.
  • the device may be preheated in an oven or the like, so that no active heating of the plate is provided for. Instead, the plate has sufficient heat capacity to treat the tissue if applied to the tissue for a predetermined amount of time.
  • protrusions 106 may include resistive heating elements such as those described above regarding FIGS. 11 A- 12 , optionally using a combination of resistive heating and the heat capacity of the protrusions and/or plate.
  • cold plate 108 may include a chilled fluid conduit, thermoelectric cooling module, or the like for actively cooling the plate, and/or may make use of the heat capacity of the plate to passively cool the tissue through cooled protrusions 110 .
  • FIG. 20 illustrates an energy transmission element which is self-limiting.
  • a heat transfer surface 116 (typically defined by a metal barrier) is heated by boiling an aqueous gel 118 .
  • Gel 118 is boiled by a resistive heater 120 , and the steam is directed through a nozzle 122 in an insulating material 124 .
  • the heated steam heats the heat transfer surface 116 .
  • insulating material 124 substantially blocks the heat from resistive heater 120 from reaching the heat transfer surface 116 .
  • this provides a maximum temperature determined by the boiling point of the aqueous gel, without requiring a temperature sensor.
  • the maximum amount of heat delivered to the tissue is determined by the initial mass of the aqueous gel provided.
  • FIG. 21 schematically illustrates a kit 130 including probe 20 and its instructions for use 132 .
  • Probe 20 may be replaced by any of the probe structure described herein, while instructions for use 132 will generally recite the steps for performing one or more of the above methods.
  • the instructions will often be printed, optionally being at least in-part, comprise a video tape, a CD-ROM or other machine readable code, a graphical representation, or the like showing the above methods.

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plasma & Fusion (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Electrotherapy Devices (AREA)
  • Surgical Instruments (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)

Abstract

The invention provides improved devices, methods, and systems for repeatably and reliably contracting fascia and other support tissues, particularly for the treatment of urinary incontinence. Rather than relying on a surgeon's ability to observe, direct, and control the selective shrinking of pelvic support tissues, a relatively large surface of a tissue contraction system is placed statically against the target tissue. Sufficient controlled energy is transmitted from the surface into the engaged tissue to contract the tissue and inhibit incontinence (or otherwise provide the desired therapeutic results).

Description

  • This application is a Continuation-In-Part of, and claims the benefit of priority from, Provisional U.S. patent application Ser. No. 60/094,946, filed Jul. 31, 1998, the full disclosure of which is incorporated herein by reference. [0001]
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention [0002]
  • The present invention generally relates to medical devices, methods and systems for selectively contracting tissues, particularly for the treatment of urinary incontinence. [0003]
  • Urinary incontinence arises in both men and women with varying degrees of severity, and from different causes. In men, the condition most frequently occurs as a result of prostatectomies which result in mechanical damage to the urethral sphincter. In women, the condition typically arises after pregnancy when musculoskeletal damage has occurred as a result of inelastic stretching of the structures which support the genitourinary tract. Specifically, pregnancy can result in inelastic stretching of the pelvic floor, the external sphincter, and the tissue structures which support the bladder and bladder neck region. In each of these cases, urinary leakage typically occurs when a patient's abdominal pressure increases as a result of stress, e.g., coughing, sneezing, laughing, exercise, or the like. [0004]
  • Treatment of urinary incontinence can take a variety of forms. Most simply, the patient can wear absorptive devices or clothing, which is often sufficient for minor leakage events. Alternatively or additionally, patients may undertake exercises intended to strengthen the muscles in the pelvic region, or may attempt a behavior modification intended to reduce the incidence of urinary leakage. [0005]
  • In cases where such non-interventional approaches are inadequate or unacceptable, the patient may undergo surgery to correct the problem. A wide variety of procedures have been developed to correct urinary incontinence in women. Several of these procedures are specifically intended to support the bladder neck region. For example, sutures, straps or other artificial structures are often looped around the bladder neck and affixed to the pelvis, the endopelvic fascia, the ligaments which support the bladder, or the like. Other procedures involve surgical injections of bulking agents, inflatable balloons, or other elements to mechanically support the bladder neck. [0006]
  • An alternative surgical procedure which is performed to enhance support of the bladder is the Kelly plication. This involves midline plication of the fascia, particularly for repair of central defects. In this transvaginal procedure, the endopelvic fascia from either side of the urethra is approximated and attached together using silk or linen suture. A similar procedure, anterior colporrhaphy, involves exposing the pubocervical fascia and reapproximating or plicating portions of this tissue from either side of the midline with absorbable sutures. While the Kelly plication and its variations are now often used for repair of cystocele, this procedure was originally described for the treatment of incontinence. [0007]
  • Each of these known procedures has associated shortcomings. Surgical operations which involve midline plications or direct suturing of the tissues of the urethra or bladder neck region require great skill and care to achieve the proper level of artificial support. In other words, it is necessary to occlude or support the tissue sufficiently to inhibit urinary leakage, but not so much that intentional voiding is made difficult or impossible. Balloons and other bulking agents which have been inserted can migrate or be absorbed by the body. The presence of such foreign body inserts can also be a source of urinary tract infections. [0008]
  • Alternative devices, systems, and methods for treatment of urinary incontinence have recently been proposed in U.S. patent application Ser. No. 08/910,370, filed Aug. 13, 1997, and assigned to the assignee of the present invention. This reference, which is incorporated herein by reference, describes techniques for treating urinary incontinence by applying sufficient energy to tissue structures that comprise or support the patient's urethra so as to cause partial shrinkage of the tissue, and thereby inhibit incontinence. Hence, these techniques generally involve selectively contracting a patient's own pelvic support tissues, often applying gentle heating of the collagenated endopelvic structures to cause them to contract without imposing significant injury on the surrounding tissues. U.S. patent application Ser. No. 08/910,775, filed Aug. 13, 1997, describes related non-invasive devices, methods and systems for shrinking of tissues, and is also incorporated herein by reference. [0009]
  • While these new methods for treatment of incontinence by selectively contracting tissues represent a significant advancement in the art, still further improvements would be desirable for treating urinary incontinence in men and women. In particular, it would be desirable to provide devices and therapies to reliably and repeatably contract tissues so as to effect the intended physiological change. It would be best if these improved techniques and structures could provide reliable results independent of the normal variations in the skill and experience of the surgeon. It would further be desirable if these improved techniques could be performed using minimally invasive techniques so as to reduce patient trauma, while retaining and/or enhancing the overall efficacy of the procedure. [0010]
  • 2. Description of the Background Art [0011]
  • The following U.S. patents and other publications may be relevant to the present invention: U.S. Pat. Nos. 4,453,536; 4,679,561; 4,765,331; 4,802,479; 5,190,517; 5,281,217; 5,293,869; 5,314,465; 5,314,466; 5,370,675; 5,423,811; 5,458,596; 5,496,312; 5,514,130; 5,536,267; 5,569,242; 5,588,960; 5,697,882; 5,697,909; and P.C.T. Published Application No. WO 97/20510. [0012]
  • SUMMARY OF THE INVENTION
  • The present invention provides improved devices, methods, and systems for repeatably and reliably contracting fascia and other support tissues, particularly for the treatment of urinary incontinence. The techniques of the present invention generally enhance the support provided by the natural tissues of the pelvic floor. Rather than relying entirely on the surgeon's ability to observe, direct, and control the selective shrinking of these tissues, the present invention generally makes use of tissue contraction systems which are placed statically against the target tissue, and which direct sufficient energy into the tissue so as to inhibit incontinence or the like. [0013]
  • The treatment surface will often engage a relatively large area of the endopelvic fascia, and will be held in a static position against this tissue. While the electrodes are energized under computer control the device heats and shrinks the engaged endopelvic fascia with minimal collateral damage to the surrounding fascia and tissues, while the device structure and controller will together generally avoid ablation of the engaged endopelvic fascia. [0014]
  • Advantageously, sufficient shrinkage can be provided by the device in the static position so that no additional heating/tissue contraction treatments may be required to the endopelvic fascia on the engaged side of the urethra. Hence, the present invention can take advantage of automated energy delivery circuits and/or selectable contraction probes having treatment surfaces of a variety of selectable sizes and shapes so as to predictably contract the target tissue, rather than relying entirely on a surgeon's skill to contract the proper amount of tissue, for example, by manually “painting” a small electrode along the tissue surface, and may also reduce fouling along the electrode/tissue interface. [0015]
  • In one aspect, the invention provides a device for therapeutically heating a target tissue of a patient body. The device comprises a probe body having a heat transfer surface oriented for engaging a target tissue. A component is thermally coupled to the heat transfer surface. The component has an electrical characteristic which varies predictably with temperature. A conductor is electrically coupled to the component. [0016]
  • Advantageously, the heat transfer surface can be used to both heat the tissue and to thermally couple a component to the target tissue so as to provide a tissue temperature signal. The component, which typically comprises a transistor or diode, can also be used as a resistive heater. More specifically, the diode can be used in a heating/temperature indicating circuit by alternatively applying a relatively high electrical power across the diode to heat the tissue, and then applying a relatively low power to the diode to measure the forward junction voltage of the diode. As the voltage across a transistor or diode often varies by about 2.0 mV/° C., the low power measurement will permit calculation of the tissue temperature. [0017]
  • In another aspect, the invention provides a tissue contraction system comprising a heat transfer surface oriented for engaging a tissue surface of a tissue. An electrical component is thermally coupled to the heat transfer surface, and a power supply is electrically coupled to the component. Electrical energy from the power supply heats the component, and the component heats the tissue to a tissue contraction temperature by thermal conduction through the heat transfer surface and the tissue surface. [0018]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a lateral cross-sectional view showing the urinary bladder and a bladder support structure. [0019]
  • FIG. 2 is a cross-sectional view of a patient suffering from urinary stress incontinence due to inelastic stretching of the endopelvic fascia. [0020]
  • FIG. 3 shows a known method for treating urinary incontinence by affixing sutures around the bladder neck. [0021]
  • FIG. 4 illustrates improved bladder support provided by contracting the endopelvic fascia according to the principles of the present invention. [0022]
  • FIG. 5 is a perspective view of a probe having a thin flat credit card shaped body and a treatment surface with a two-dimensional array of bi-polar electrode pairs. [0023]
  • FIG. 5A is a front view of the probe of FIG. 5. [0024]
  • FIGS. 5B and C are side and front views, respectively, of a probe having an electrode array supported by a shaft. [0025]
  • FIGS. [0026] 5D-G illustrate the structure and electrical layout of the electrode array for the probe of FIGS. 5A and B.
  • FIGS. [0027] 6A-C are schematic block diagram showings of a static tissue contraction system having an electrode array with optional temperature feedback signals.
  • FIGS. [0028] 7A-E schematically illustrate methods for accessing left and right target regions of the endopelvic fascia.
  • FIG. 8 is a cross-sectional view showing a method for treating a left target region of the endopelvic fascia. [0029]
  • FIGS. [0030] 9A-D schematically illustrate a picture frame shaped tissue contraction device having an independently energizeable peripheral portion so as to treat tissue surrounding an initially contracted region.
  • FIGS. 10A and B illustrate an alternative probe having a two-dimensional electrode array. [0031]
  • FIGS. 11A and B illustrate a probe structure having a two-dimensional array of posts for independently engaging, heating and contracting tissue, in which the posts may optionally include resistive heaters and temperature sensors. [0032]
  • FIG. 12 is a cross-sectional view of a probe structure having heat transfer surfaces thermally coupled to diodes and to the target tissue so as to allow the diodes to act as both heaters and temperature sensors. [0033]
  • FIG. 12A is a drive/feedback block diagram for the probe of FIG. 12. [0034]
  • FIG. 13 illustrates an alternative probe structure in which a conduit directs a heated fluid along a treatment surface of the probe. [0035]
  • FIG. 14 illustrates a still further alternative probe in which a plurality of irrigation ports are disposed between a one-dimensional array of elongate electrodes. [0036]
  • FIG. 15 illustrates a semi-rigid probe body which flexes to help ensure the treatment surface of the probe is in contact with the target tissue. [0037]
  • FIG. 16 illustrates a probe having a cavity that receives the urethra to help ensure that the treatment surface is separated from the urethra by a protection zone. [0038]
  • FIGS. [0039] 17A-C illustrate front and side views of a probe having a balloon which urges the treatment surface of the probe against the target tissue.
  • FIGS. [0040] 18A-C illustrate a minimally invasive probe having interspersed heating and cooling areas to effect tissue contraction with minimal damage to the target tissue, and in which the probe includes a balloon that can be inserted to a treatment site in a narrow configuration and expanded at the treatment site to engage and treat the full target region without moving the probe.
  • FIGS. [0041] 19A-C illustrate a probe having interspersed hot and cold posts.
  • FIG. 20 is a cross-sectional view showing a probe having a heating element with a limited quantity of a reaction material such that the total heat energy that will be transmitted to the target tissue is limited. [0042]
  • FIG. 21 illustrates a tissue contracting kit including the probe of FIG. 5 and instructions for its use. [0043]
  • DESCRIPTION OF THE PREFERRED EMBODIMENT
  • The present invention generally provides methods, devices, and systems which repeatably contract tissue, particularly as a therapy for incontinence. The techniques of the invention will generally involve positioning a probe so that a surface of the probe engages a target tissue statically, that is, without relative movement between the probe and the engaged tissue surface during treatment. Energy will then be transmitted from the treatment surface of the probe into the target tissue so as to effect the desired contraction. This allows the contraction to be controlled by the configuration and/or software of the system, rather than relying on a surgeon's experience to allow him or her to “paint” a small area electrode surface across a sufficient portion of the target region at a proper rate to effect contraction without imposing excessive injury on the target tissue. As these techniques will be effective for controllably and repeatably contracting a wide variety of fascia and other collagenated tissues throughout the body, they will find applications in a wide variety of therapies, including skin wrinkle shrinkage, tightening stretched tendons and ligaments in knees, ankles, and wrists, treatment of droopy eyelids, shrinking large earlobes, and the like. However, the most immediate application for the invention will be to enhance the patient's own natural support of the bladder, bladder neck region, and urethra so as to inhibit urinary incontinence. [0044]
  • The techniques of the present invention will often be used to contract fascia, tendons, and other collagenous tissues, preferably without ablation of these collagenous tissues. As used herein, this means that collagenous tissues are not removed and their function (particularly their structural support function) is not destroyed. Histologically, some tissue necrosis may occur, and the structural strength of the contracted tissue may initially decrease after treatment. Nonetheless, the treated tissues will generally continue to provide at least some structural support, and their structural strength should increase during the healing process so that the healed, contracted tissue has at least almost the same structural strength as, and preferably greater structural strength (for example, stretching less under tension) than before treatment. Collagenous tissues may occasionally be referred to herein as collagenated tissues. The pelvic support tissues which generally maintain the position of much of the genitourinary tract, and particularly the position of urinary bladder B, are illustrated in FIG. 1. Of particular importance for the method of the present invention, endopelvic fascia EF defines a hammock-like structure which extends laterally between the left and right arcus tendinous fascia pelvis ATFP. These later structures extend substantially between the anterior and posterior portions of the pelvis, so that the endopelvic fascia EF largely defines the pelvic floor. [0045]
  • The fascial tissue of the pelvic floor may comprise tissues referred to under different names by surgeons of different disciplines, and possibly even by different practitioners within a specialty. In fact, some surgeons may assign the collagenous support structure referred to herein as the endopelvic fascia one name when viewed from a superior approach, and a different name when viewed from an inferior approach. Some or all of this support structure may comprise two collagenous layers with a thin muscular layer therebetween, or may comprise a single collagenous layer. In general terms, the therapy of the present invention may be directed toward any of the collagenous portions of the support structures for the urethra, bladder neck, and bladder. Hence, the treated tissues may include and/or be referred to as endopelvic fascia, arcus tendinous fascia pelvis, urethropelvic ligaments, periurethral fascia, levator fascia, vesicopelvic fascia, transversalis fascia, and/or vesicle fascia, as well as other collagenous support structures. [0046]
  • In women with urinary stress incontinence due to bladder neck hypermobility, the bladder has typically dropped between about 1.0 cm and 1.5 cm (or more) below its nominal position. This condition is typically due to weakening and/or stretching of the pelvic support tissues, including the endopelvic fascia, the arcus tendinous fascia pelvis, and the surrounding ligaments and muscles, often as a result of bearing children. [0047]
  • When a woman with urinary stress incontinence sneezes, coughs, laughs, or exercises, the abdominal pressure often increases momentarily. Such pressure pulses force the bladder to descend still farther, shortening or misaligning the urethra UR and momentarily opening the urinary sphincter. [0048]
  • As can be most clearly understood with reference to FIGS. [0049] 2-4, the present invention generally provides a therapy which effectively reduces the length of the pelvic support tissues and returns bladder B towards its nominal position. Advantageously, the bladder is still supported by the fascia, muscles, ligaments, and tendons of the natural pelvic support tissues.
  • Referring now to FIG. 2, bladder B can be seen to have dropped from its nominal position (shown in phantom by outline [0050] 10). While endopelvic fascia EF still supports bladder B to maintain continence when the patient is at rest, a momentary pressure pulse P opens the bladder neck N resulting in a release of urine through urethra UR.
  • A known treatment for urinary stress incontinence relies on suture S to hold bladder neck N closed so as to prevent inadvertent voiding, as seen in FIG. 3. Suture S may be attached to bone anchors affixed to the pubic bone, ligaments higher in the pelvic region, or the like. In any case, loose sutures provide insufficient support of bladder neck N and fail to overcome urinary stress incontinence. Over tightening suture S may make normal urination difficult and/or impossible. [0051]
  • As shown in FIG. 4, by reducing the effective length of the natural pelvic support tissues, bladder B may be elevated from its lowered position (shown by lowered outline [0052] 12). Alternatively, contraction of selected tissues may reduce or eliminate slack in the support structures without raising the bladder, and/or may reduce the elongation of the support structures to reduce dropping of the bladder when under stress. A pressure pulse P will then be resisted in part by endopelvic fascia EF which supports the lower portion of the bladder, helping maintain the bladder neck in a closed configuration.
  • Fine tuning of the support provided by the endopelvic fascia is possible through selective modification of the anterior portion of the endopelvic fascia. To close the bladder neck and raise bladder B upward, for example, it may be possible to effect a greater total tissue contraction towards the front. Alternatively, repositioning of bladder B to a more forward position may be affected by selectively contracting the dorsal portion of the endopelvic fascia EF to a greater extent then the forward portion. Hence, the therapy of the present invention may be tailored to the particular weakening exhibited by a patient's pelvic support structures. Regardless, the portion of the endopelvic fascia EF adjacent the bladder neck and urethra UR can remain free of sutures or other artificial support structures which might directly compress the urethra. [0053]
  • Referring now to FIG. 5, a credit card shaped [0054] probe 20 includes a thin flat probe body 22 having a treatment surface 24. A two-dimensional array of electrodes 26 is distributed across treatment surface 24, the electrodes here being arranged in bipolar pairs. Conductors 28, here in the form of a plurality of insulated wires jacketed in a single bundle, extend from probe body 22 for coupling an electrical energy source to electrodes 26.
  • As seen most clearly in FIG. 5A, [0055] treatment surface 24 of probe 20 has a length 29 and a width 30 that are significantly greater than a thickness of probe body 22. Length 24 will typically be at least about 10 mm, while width 30 will generally be at least about 5 mm. Preferably, length 28 will be between about 10 and 50 mm, with width 30 being between about 5 and 30 mm.
  • [0056] Probe body 22 will usually have a thickness of between about 1 and 15 mm. In many embodiments, the thickness of probe body 22 will be about 8 mm or less, typically being from about 8 mm to about 1 mm, and preferably being about 5 mm or less. The probe body will often be at least semi-rigid. In other words, although probe body 22 may flex, the probe body will generally have a stiffness greater than that of fascial tissue. This helps ensure that each of electrodes 26 can be effectively coupled to the fascial tissue surface by urging an interior portion of the probe body against the target tissue. Body 22 may flex slightly during such pressure so that both surfaces conform somewhat to each other. Body 22 may be substantially rigid so that the fascial surface conforms substantially entirely to the shape of probe 20. The probe body may comprise a polymer such as polycarbonate, ABS plastic, or the like.
  • Where electrodes are used to heat the target tissue, the tissue temperature can be controlled in a variety of ways so as to limit variability in efficacy. Feedback to a computer which controls power to [0057] electrodes 26 might directly indicate temperature, or the computer might instead control the treatment time. Signals might be provided to the computer indicating the electrical power being used, the electrical energy which has been input to the tissue, or the impedance of the tissue as measured by the current and voltage of the RF energy delivered to the probe. Additionally, the spacing between treated and non-treated regions may be set by the structure of the probe and array, and/or by selectively energizing the electrodes of the probe. This further controls the therapy to eliminate or reduce user variability.
  • [0058] Electrodes 26 may be substantially flush with tissue treatment surface 24, or may alternatively protrude from the tissue treatment surface. When protruding electrodes are used, they will often present a rounded surface for engagement against the fascial tissue so as to minimize the concentration of electrical current density (as might otherwise occur at sharp corners). As is explained in more detail in U.S. patent application Ser. No. 08/910,370, filed Aug. 13, 1997, the full disclosure of which is incorporated herein by reference, the depth of tissue treatment may be varied when using bi-polar electrodes by setting the spacing 32 between a pair of electrodes 34, and/or by setting a diameter or radius of curvature of electrodes 26 where they engage the tissue surface. In the exemplary embodiment, the electrodes have a radius of curvature of 0.012 inches, are formed of stainless steel, and are separated by about six times the radius of curvature (between their inner edges) to limit heating depth to less than about 3 mm. The spacing between electrode pairs should allow treatment of a relatively large amount of fascia without damage to the urethra. Spacing between pairs may also leave some untreated tissue interspersed between the treated regions, which will promote healing. The interspersed untreated areas of the target tissue may comprise fascia and/or other collagenous tissues, and the pairs may be separated such that at least a portion of the untreated tissue can remain at or below a maximum safe tissue temperature throughout treatment, optionally remaining below 60° C., and in some embodiments remaining below 45° C.
  • Using a bipolar credit card shaped configuration, a fascial tissue can be safely heated to a contraction temperature by transmitting a current between a pair of electrodes having a radius of curvature at the tissue interface in a range from about 0.05 to about 2.0 mm, ideally being about 0.3 mm, where the electrodes are separated by a distance in the range from about 1 to about 10 times the radius of curvature of the electrodes. This generally allows heating of the fascial tissue to a depth in the range between about 0.5 and 10 mm from the engaged tissue surface, typically using an alternating current at a frequency at between about 100 kHz and 10 MHz with a voltage in a range of from about 10 to about 100 volts rms (ideally being about 60 volts rms) and a current in a range from about 0.1 to about 10 rms amps. The driving energy may be applied using an intermittent duty cycle to effect the desired increase in temperature. Generally, the tissue will be heated to a safe contraction temperature in a range from about 70° C. to about 140° C. for a time in the range from about 0.5 to about 40 secs, typically for a time from about 0.5 to about 10 secs. [0059]
  • An [0060] alternative probe structure 20′ is illustrated in FIGS. 5B and C. In this embodiment, probe body 22 is supported by a rigid shaft 23 extending from a handle 25. Shaft 23 may be bent to orient treatment surface 24 to engage the endopelvic fascia. Optionally, a flex joint 27 may be provided at the junction of shaft 23 and probe body 22 to help ensure that the entire treatment surface 24 engages the fascial surface when the treatment surface is held in position manually from handle 25. Joint 27 may comprise a pliable or resilient structure and/or material adjacent the shaft/body interface, such as an elastomer, a polymer, a ball and socket arrangement, a pair of orthogonal pivots, or the like. Shaft 23 may comprise a stainless steel hypotube containing the conductors coupled to electrodes 26, or any of a variety of alternative metal, polymer, or composite structures. The handle will often comprise a polymer such as polycarbonate, ABS plastic, or the like, and may optionally include controls for energizing the electrodes.
  • The configuration of the electrode array is generally fixed by the probe body structure. This often sets the tissue heating pattern (based on the electrode size and spacing between electrode pairs), as the probe body will be held at a fixed position against the tissue during tissue heating. This predetermined heating pattern helps avoid over-treatment of some tissues and under contraction of others, as can occur when manually painting a small treatment surface repeatedly across the target tissue. [0061]
  • It has been demonstrated that the shape and layout of the electrodes can provide preferential contraction of the target tissue along a desired orientation. Using the [0062] elongate electrodes 26 arranged in two series of three end-to-end pairs, and heating each pair of first one series, and then the other series, sequentially (starting with the middle pair), the engaged tissue can be contracted to a significantly greater extent in width (across the electrode pairs) than in length (along the electrodes). In fact, any pattern of elongate heated tissue zones (such as between an elongate pair of electrodes) may provide preferential contraction across the elongate heat zones as compared to along their length, particularly when such elongate heat zones are alternated with elongate untreated zones (such as between the pairs). This can be extremely useful when a surgeon wants to, for example, decrease a lateral width of the endopelvic fascia while minimizing the reduction in its anterior/posterior length.
  • [0063] Probe body 22 will often be formed as a multilayer structure to facilitate electrically coupling conductors 28 to electrodes 26. As shown in FIG. 5, for monopolar operation, only a single conductor need be electrically coupled to the electrodes, while a separate conductor can be coupled to a large return electrode placed on the leg or back of the patient. Bipolar operation will generally include at least two-conductors, while both monopolar and bipolar probes will often include larger numbers of conductors to selectively vary the electrical power across treatment surface 24.
  • An exemplary structure for [0064] probe body 22 of probe 20′ is illustrated in FIGS. 5D and E. Electrodes 26 are formed from wires of stainless steel, copper, or the like, but may alternatively comprise plates oriented perpendicularly to the treatment surface, the plates having rounded or radiused edges, with only the edges exposed. Electrodes 26 are coupled to the power supply with wires or other conductors disposed between a main probe body 22 a and a back insulating layer 22 b. The conductors extend proximally through hypotube 23, which may also include a lumen for delivering a conduction enhancing liquid or gel, typically for delivery of about 1 cc/min of saline through one or more weep holes in treatment surface 24 adjacent or between the pairs of electrodes (as can be understood with reference to FIG. 14). Probe body 22 will typically be rigid in this embodiment, often being formed of a polymer such as ABS plastic, polycarbonate, or the like, but may alternatively be semi-rigid (typically comprising silicone or nylon).
  • [0065] Probe 20 may optionally include a variety of mechanisms to actively control contraction of the target tissue. Optionally, body 22 may include multiplexing circuitry which selectively directs electrical energy supplied through a limited number of conductors to the electrodes or electrode pairs. Such circuitry will optionally vary the electrical energy or duty cycle of the electrodes depending on temperatures measured at or near the electrodes. Alternatively, a uniform heating energy may be directed from treatment surface 24 based on one or more temperature measurements, based on dosimetry, or the like. Circuitry for probe 20 may incorporate microprocessors or the like. Alternatively, signals may be transmitted from the probe to an external processor for control of the contraction energy.
  • Exemplary probe circuits are illustrated in FIGS. 5F and G. The coupling arrangement illustrated in FIG. 5F allows an M×N array of electrode pairs to be selectably energized using only M+N conductors. This arrangement takes advantage of the fact that current (and heating) will be concentrated along the path of least electrical resistance, which will generally be between the two closest bipolar electrodes. In this case, rows of electrodes are coupled together and columns of electrodes are coupled together so that a [0066] particular electrode pair 1, 2, 3, . . . 6 is selected by driving a current between the associated column and the associated row. For example, electrode pair 3 is selected by driving bipolar current between the electrodes of column 1 and the electrodes of row 2. Current (and heating) between energized electrodes other than pair 3 will not be sufficient to significantly contract tissue. In the exemplary embodiment, the electrode pairs are energized by heating each pair associated with a column starting with the middle pair (for example, pair 3, then pair 1, then pair 5), and then moving on to the next column (for example, pair 4, pair 2, and then pair 6).
  • The probe circuit of FIG. 5G allows the electrode pairs to be selectively energized, and further provides calibrated temperature information from adjacent each electrode pair (temperatures may be monitored selectively, for example, at the active electrode only). [0067] Temperature sensors 31 may comprise thermistors, thermocouples, or the like, and will be mounted to probe body 22 so as to engage the tissue between a pair of electrodes to limit the number of signal wires, temperature sensors 31 are coupled to a multiplexer MUX mounted in handle 25, or possibly in probe body 22. As such temperature sensors provide temperature signals which are repeatable (for each mounted sensor) though not necessarily predictable, the accuracy of the temperature feedback can be enhanced by storing calibration data for this probe, and ideally for each temperature sensor, in a non-volatile memory such as an EEPROM.
  • Static contraction [0068] systems including probe 20 are shown schematically in FIGS. 6A-C. In general, power from an electrical power source 33 is directed to the electrodes of probe 20′ by a switching unit 35 under the direction of a processor 37. These functions may be combined in a variety of arrangements, such as by including the processor and the switching unit, some or all of the switching unit circuitry with the probe, or the like. Where temperature feedback is provided, such as in the system of FIG. 6C, the temperature may be controlled by selectively energizing and halting power to the probe (sometimes called a bang-bang feedback control) to maintain the desired temperature or temperature profile, or the controller and/or switching unit may selectively vary the power level.
  • Advantageously, the total desired shrinkage of a discrete target region of endopelvic fascia EF may be controlled without moving [0069] probe 20. Total contraction of the endopelvic fascia will depend on a number of factors. Generally, tissue will contract locally by up to 70% (areal shrinkage) when heated to a contraction temperature range. Therefore, it is possible to select a probe 20 having a treatment surface 24 with a size and shape suitable for providing a total effective contraction of endopelvic fascia EF so as to provide the desired improvement in support of the pelvic floor. It may therefore be desirable to provide a series of differing probes for contracting tissues by differing amounts. For example, it may be possible to select a probe having a lateral dimension of 12 mm to decrease an effective lateral dimension of the right portion of the endopelvic fascia by 5 mm. A greater amount of contraction might be effected by selecting an alternate probe with a greater width. Selecting probes having differing lengths, selecting among alternative probes having treatment surfaces 24 which are wider at one end than the other, or selectively positioning the probe along the midline might allow the surgeon to tailor the enhanced support to lift the anterior or posterior portions of the bladder to a greater or lesser degree, as desired.
  • Still further alternative contraction control mechanisms might be used. Rather than selecting alternative probes, it may be possible to vary the heating energy among the electrodes. Where a lesser degree of contraction is desired, the surgeon may heat the tissue to a lower temperature, and/or may selectively heat only a portion of the tissue which engages treatment surface [0070] 24 (for example, by energizing only a selected subset of electrodes 26). Electrical properties of the system can be monitored before, during, between, and/or after energizing the probe with tissue heating current. For example, as the controller selectively energizes the electrode pairs, the system impedance can be monitored to help ensure that sufficient electrode/tissue coupling is maintained for the desired treatment. In a simple feedback indication arrangement, a warning light may illuminate to inform the surgeon that coupling was (or is) insufficient. More sophisticated feedback systems may re-treat selected undertreated areas by re-energizing electrode pairs for which coupling was compromised. Generally, these feedback systems generate a feedback signal FS to indicate an effect of the treatment on the tissue, as schematically illustrated in FIG. 6A. Feedback signal FS may simply provide an indication to the surgeon, or may be processed by the controller to modify the treatment. Regardless, this controlled contraction can be provided without moving probe 20.
  • Methods for accessing target regions of the endopelvic fascia are illustrated in FIGS. [0071] 7A-E. In general, endopelvic fascia EF can be viewed as left and right fascial portions separated at the patient's midline by urethra UR. Endopelvic fascia EF is supported by ligaments ATFP above a vaginal wall VW. It may be desirable to selectively shrink endopelvic fascia EF along target regions 40 which extend in an anterior posterior direction along the left and right sides of the endopelvic fascia. This should provide enhanced support of urethra UR, the bladder neck, and the bladder with little risk of heating, denervating or injuring the delicate urethral tissues.
  • To [0072] access target regions 40 with minimal trauma to the patient, a weighted speculum 42 is inserted into the vagina to expose the anterior vaginal wall VW. Optionally, elongated laterally offset incisions 43 might be made in the anterior vaginal wall so that the vaginal mucosa could be manually dissected to reveal the endopelvic fascia EF. However, to minimize trauma and speed healing, a small incision 44 may be made on either side of urethra UR, thereby allowing access for a minimally invasive blunt dissection device 46. Dissection device 46 includes a mechanical expansion element in the form of a balloon 48 at its distal end. Balloon 48 dissects the back side of the vaginal wall from the endopelvic fascia to create a minimally invasive treatment site 50 along each of the discrete target regions 40, as seen in FIG. 7D. Regardless of the specific access technique, the exposed endopelvic fascia will preferably be irrigated with saline or the like to reduce fouling of the electrodes, and to enhance electrode/tissue coupling with a conductive film. The patient will preferably be positioned so that excess irrigation fluid drains from the tissue surface, and aspiration will often be provided to clear any drained fluids.
  • An alternative method for accessing the endopelvic fascia is illustrated in FIG. 7E. This is sometimes referred to as the Raz technique, and generally comprises separating an arch-shaped mid-line flap F from the surrounding vaginal wall VW to access the underlying and adjacent endopelvic fascia as shown. This procedure was described in more detail by Shlomo Raz in [0073] Female Urology, 2nd. Ed. (1996) on pages 395-397.
  • Referring now to FIG. 8, [0074] probe 20 is inserted through incisions 43 or 44 to treatment site 50. Treatment surface 24 is urged against exposed surface 52 of endopelvic fascia EF so that electrodes 26 are effectively coupled with the endopelvic fascia. Probe 20 may be biased against the endopelvic fascia manually by pressing against the wall of vaginal mucosa VM, by pressing directly against the probe using a finger inserted through incision 43 or 44, or using a shaft attached to the probe that extends proximally through the incision. Alternatively, as will be described hereinbelow, probe 20 may include a mechanical expansion mechanism for urging treatment surface 24 against the endopelvic fascia EF.
  • Once the probe engages [0075] target region 40 of endopelvic fascia EF, electrodes 26 are energized via conductors 28 (see FIG. 5). Electrodes 26 direct electrical current through the endopelvic fascia so that the resistance of the fascia causes an increase in tissue temperature. The use of relatively large electrode surfaces having a sufficiently large radius of curvature avoids excessive concentration of electrical current density near the tissue/electrode interface which might cause charring, tissue necrosis, or excessive injury to the tissue.
  • As endopelvic fascia EF is heated by [0076] probe 20, the collagenated tissues within the fascia contract, drawing the tissue inward along treatment surface 24. Although probe 20 does not move during this contraction, it should be noted that at least a portion of endopelvic fascia EF may slide along treatment surface 24, since the tissue contracts while the probe generally does not.
  • As can be understood with reference to FIGS. [0077] 9A-D, the probes of the present invention can effectively treat a larger region of the target tissue than is initially engaged by the treatment surface. FIG. 9A schematically illustrates a treatment surface 24 having a peripheral “picture frame” portion 56 which can be energized independently of an interior portion 54. By energizing both portions 54 and 56, tissue 58 engaging treatment surface 24 contracts inward as shown in FIG. 9B. Once this first stage of tissue has been contracted, however, additional heating of the contracted tissue will generally not provide contraction to the same degree, but may impose additional injury. Therefore, peripheral portion 56 can be energized independently of the interior portion so that the uncontracted tissue 60 that now engages treatment surface 24 can be safely contracted.
  • While interior portions [0078] 54 and peripheral portion 56 are illustrated as contiguous treatment zones, it should be understood that they may actually comprise independently energizeable arrays of electrodes. Additionally, it should be understood that peripheral portion 56 need not completely surround interior portion 54, particularly where the probe includes some structure that affixes a portion of the probe relative to the engaged tissue.
  • A wide variety of alternative electrode array structures might be used. As illustrated in FIG. 10A, [0079] electrodes 62 may optionally comprise monopolar or bipolar rounded buttons or flat disks defining a two-dimensional array. In some embodiments, a temperature sensor may be provided for each button. For bipolar heating, radiofrequency current may be driven from one button electrode to another. Alternatively, radiofrequency current may be driven from each button to a large surface area pad applied against the patient's back in a monopolar configuration.
  • When used in a bipolar mode, it may be desirable to drive radiofrequency current between pairs of electrodes that are separated by at least one other electrode. This may allow heating to a more even depth, as heating energy will be concentrated near the engaged tissue surface adjacent each electrode, but will be distributed to a greater depth midway between the electrodes of a bipolar pair. For example, it is possible to drive radiofrequency current from electrode [0080] 62 a to electrode 62 c, from electrode 62 b to electrode 62 d, from electrode 62 e to electrode 62 g, from electrode 62 f to electrode 62 h, and the like.
  • Advantageously, in an N×M electrode array, it is possible to independently drive each of these electrode pairs using only N+M conductors between the driving power source and the electrodes, as described above regarding FIG. 5F. [0081]
  • A wide variety of alternative electrode and probe structures may be used. For example, the button electrodes of FIGS. 10A and B may be mounted on an inflatable balloon which could be rolled up into a narrow configuration for insertion to the treatment site. The balloon could then be inflated to allow engagement of the treatment surface against the target tissue. [0082]
  • A still further alternative probe structure is illustrated in FIGS. 11A and B. In this embodiment, a two-dimensional array of [0083] protrusions 64 each include a resistive heater 66 and a temperature sensor 68. As heat transfer between the probe and the tissue is by conduction of heat rather than by conduction of electrical current, the ends of protrusions 64 can safely include corners without concentrating heat. Hence, the protrusions can have heat transfer ends that are round, square, hexagonal, or the like, and the protrusions can be cylindrical, conical, or some other desired shape. Alternatively, flush heat transfer surfaces may be formed with similar structures.
  • Preferably, the [0084] protrusions 64 can be pressed against the tissue surface and resistive heaters 66 can be energized while active temperature feedback is provided by temperature sensor 68. This feedback can be used to heat the protrusions to the desired treatment temperature for a predetermined time so as to effect the desired tissue contraction. Alternatively, the temperature sensors may measure the actual temperature of the tissue, rather than that of the protrusion.
  • Referring now to FIG. 12, a two-dimensional array of heat transfer surfaces [0085] 70 might make use of thermally conductive materials that extend from or are flush with treatment surface 24. At least one electrical component 72 is thermally coupled to an associated heat transfer surface 70 so that the component varies in temperature with the temperature of the surface. The component will typically have an electrical characteristic which varies with temperature, the component typically comprising a transistor, thermistor, or silicon diode. Component 72 can be coupled to conductor 28 using a printed circuit board 74.
  • Electrical current is driven through [0086] component 72 so that the component heats heat transfer surface 70. The tissue engaging heat transfer surface 24 is heated by passive conduction from heat transfer surfaces 70. Preferably, the heating electrical current is applied as intermittent pulses. Between heating pulses, a small constant current can be driven through a diode in a forward direction, and the voltage across the junction can be measured using printed circuit board 74. The forward voltage across this junction is often dependent on the temperature of the junction, typically varying by about 2 mv/° C. for a silicon diode. This forward voltage can be used to measure the junction temperature. The timing of the heating pulses and the structure of heat transfer surface 70 can be set so that the diode junction will indicate the temperature of the tissue against which the heat transfer surface is engaged, with the diode junction preferably being at or near an equilibrium temperature during a slow gradual heat cycle.
  • The temperature indication signal provided by the low-power, between heating pulse can be used as a feedback control signal. The array ideally comprises a two-dimensional array, and feedback signals from multiple heat transfer surfaces of the array should allow very good control of the local tissue contraction temperature throughout the treatment surface/tissue interface. Such an array of transistors or diodes coupled to a power source via [0087] conductor 28 and printed circuit board 74 provides a very inexpensive way to selectively control the temperature across treatment surface 24.
  • FIG. 12A is an exemplary circuit including the probe of FIG. 12. A large variable current I[0088] 1 is sufficient to heat diodes 72 so as to treat the engaged tissue, preferably under proportional control. A small constant current I2 does not significantly heat the engaged tissue, but does allow measurement of the forward voltage drop across each diode. Applying a constant small current I2, the voltage drop across a diode 72 thermally coupled (through a metal plate) to the tissue will be about 0.7 v - 2 mV/° C. for a silicon diode so as to indicate the tissue temperature. Once again an EEPROM or other non-volatile memory may store calibration data for each diode, ideally storing calibration for constants at lest two temperatures from calibration tests conducted prior to delivery and/or use of the probe.
  • As illustrated in FIGS. 13 and 14, still further alternative heating mechanisms might be used. In FIG. 13, a [0089] conduit 76 directs a relatively high temperature fluid along a serpentine path adjacent treatment surface 74, the heated fluid typically comprising steam or the like. In the embodiment of FIG. 14, a one dimensional array of elongate electrodes 80 is distributed across treatment surface 24, with irrigation ports 82 being disposed between and/or around the electrodes.
  • When accessing the endopelvic fascia transvaginally, the midline need not be dissected, as described above. This minimizes the possibility of inadvertently treating and/or injuring the urethra. Generally, treatment can be made symmetric by statically positioning the probe against the target region on the left side of the endopelvic fascia, and statically positioning the same or a different probe on the right side of the endopelvic fascia without accessing the fascia adjacent the urethra. Alternatively, it may be possible to treat only one side and effectively inhibit incontinence, particularly where only one side of the endopelvic fascia has an excessive length. Nonetheless, it may be desirable to access the endopelvic fascia across the midline, particularly when treating both the left and right target regions simultaneously with a single probe. [0090]
  • The use of a [0091] semi-rigid probe body 22 can be understood with reference to FIG. 15. Probe 20 flexes when held against endopelvic fascia EF by a force F to ensure engagement between treatment surface 24 and the endopelvic fascia throughout the desired interface region. Optionally, probe body 22 may be pre-curved to facilitate coupling between the treatment surface and the target tissue. For example, a thin flat probe body which is slightly convex might be held against the target tissue by pressure F2 at the edges of the treatment surface (rather than a central pressure F) until the device becomes substantially flat, thereby indicating to the surgeon that the proper amount of tissue engaging pressure is being applied.
  • FIG. 16 illustrates a structure and method for aligning [0092] probe body 22 along the endopelvic fascia so that treatment region 40 is separated from the urethra by a protection zone 86. A catheter 88 is introduced into the urethra, which facilitates identification of the urethra along the endopelvic fascia. Optionally, cooled water may be circulated through the catheter to avoid any injury to the urethra during treatment. It should be understood that such a urethral cooling system may be desirable for many embodiments of the present systems and methods.
  • To facilitate aligning [0093] treatment surface 24 with target region 40, urethra UR is received in a cavity 88 of probe body 22. Cavity 88 is separated from treatment surface 24 by a desired protection zone 86. As a method for using this probe will generally involve dissecting the mucosa from the endopelvic fascia so as to access the fascia near urethra UR, the probe body may extend bilaterally on both sides of the urethra to simultaneously treat the left and right portions of the endopelvic fascia, as is indicated by the dashed outline 90. Such a bilateral system can avoid injury to the urethral tissues by heating two (left and right) discrete treatment regions separated by a protection zone. Bilateral systems might evenly treat the two sides of the endopelvic fascia by sequentially energizing two separated arrays of electrodes in a mirror-image sequence, the two sides being treated simultaneously, sequentially, or in an alternating arrangement.
  • Referring now to FIGS. [0094] 17A-C, the static tissue contraction probes of the present invention may optionally include an expansion mechanism such as balloon 92 to urge treatment surface 24 against the target tissue. The device might again be inserted through incisions into the anterior vaginal wall on either side of the urethra. Electrodes 26 are again mounted on a probe body 22 which is at least semi-rigid, with a resilient balloon 92 molded to the back of the probe body. The balloon can be inflated after the probe is positioned to urge treatment surface 24 against the target tissue with a repeatable electrode/fascia interface pressure. Balloon 92 will preferably comprise an elastomer such as silicone or the like.
  • To improve coupling between the electrodes and the target tissue, defibrillator gel or saline may be provided at the treatment surface/tissue interface. These enhanced coupling materials may be placed on the probe or tissue surface prior to engagement therebetween, or may alternatively be delivered through ports adjacent the electrodes. [0095]
  • FIGS. [0096] 18A-C illustrate a still further alternative probe structure. In this embodiment, an expandable probe 94 is inserted through a small incision while the probe is in a narrow configuration. Once the probe is positioned adjacent the target tissue, balloon 96 is inflated via an inflation lumen 98. The balloon expands against an opposing tissue so as to urge treatment surface 24 against the endopelvic fascia.
  • Once inflated, fluid is passed through conduits adjacent the treatment surface to thermally treat the endopelvic fascia. In this embodiment, a hot [0097] fluid conduit 100 is arranged in a serpentine pattern which alternates with a cold fluid conduit 102 so that the treatment surface comprises interspersed zones of heating and cooling. Heating tissues to a safe contraction temperature between cooled zones will induce contraction with less injury to the tissue than would otherwise be imposed, as the regions of heated tissue are interspersed with, and protected by, the tissue cooling.
  • Still further alternative treatment mechanisms are illustrated in FIGS. [0098] 19A-C, and in FIG. 20. In the embodiment of FIGS. 19, tissue heating and cooling are interspersed using a device which includes a heated plate 104 having a series of heated protrusions 106 in combination with a cooled plate 108 having interspersed cooled protrusions 110 and passages 112. Passages 112 receive heated protrusions 106, while a thermally insulating material 114 insulates the plates surrounding the protrusions from each other and the target tissue.
  • This device may optionally make use of active resistive heating of the entire [0099] hot plate 104, in some cases with temperature feedback provided from a single temperature sensor. In such cases, hot plate 104 will preferably be thick enough so that heat transfer through the plate from protrusion to protrusion is sufficient so that the temperature gradient from one protrusion to another is negligible, allowing uniform treatment across the treatment surface. In alternative embodiments, protrusions 106 may not be actively heated while in contact with the target tissue. Instead, hot plate 104 may be heated prior to contact with the tissue so that heat transfer to the tissue is provided by the heat capacity of hot plate 104, as predetermined from the specific heat of the hot plate material, the quantity of hot plate material, and the like. In fact, the device may be preheated in an oven or the like, so that no active heating of the plate is provided for. Instead, the plate has sufficient heat capacity to treat the tissue if applied to the tissue for a predetermined amount of time.
  • In some embodiments, [0100] protrusions 106 may include resistive heating elements such as those described above regarding FIGS. 11A-12, optionally using a combination of resistive heating and the heat capacity of the protrusions and/or plate. Likewise, cold plate 108 may include a chilled fluid conduit, thermoelectric cooling module, or the like for actively cooling the plate, and/or may make use of the heat capacity of the plate to passively cool the tissue through cooled protrusions 110.
  • FIG. 20 illustrates an energy transmission element which is self-limiting. In this embodiment, a heat transfer surface [0101] 116 (typically defined by a metal barrier) is heated by boiling an aqueous gel 118. Gel 118 is boiled by a resistive heater 120, and the steam is directed through a nozzle 122 in an insulating material 124. The heated steam heats the heat transfer surface 116. Once the gel has boiled away, insulating material 124 substantially blocks the heat from resistive heater 120 from reaching the heat transfer surface 116. Advantageously, this provides a maximum temperature determined by the boiling point of the aqueous gel, without requiring a temperature sensor. Furthermore, the maximum amount of heat delivered to the tissue is determined by the initial mass of the aqueous gel provided.
  • FIG. 21 schematically illustrates a [0102] kit 130 including probe 20 and its instructions for use 132. Probe 20 may be replaced by any of the probe structure described herein, while instructions for use 132 will generally recite the steps for performing one or more of the above methods. The instructions will often be printed, optionally being at least in-part, comprise a video tape, a CD-ROM or other machine readable code, a graphical representation, or the like showing the above methods.
  • While the exemplary embodiments have been described in some detail, by way of example and for clarity of understanding, a variety of modifications, changes, and adaptations will be obvious to those of skill in the art. Therefore, the scope of the present invention is limited solely by the appended claims. [0103]

Claims (9)

What is claimed is:
1. A device for therapeutically heating a target tissue of a patient body, the device comprising:
a probe body having a heat transfer surface oriented for engaging the target tissue;
a component thermally coupled to the heat transfer surface, the component having an electrical characteristic which varies with temperature; and
a power source coupled to the component for applying a first electrical power, the first power being sufficient to heat the component so that the component heats the heat transfer surface.
2. The therapeutic heating device of
claim 1
, further comprising circuitry coupled to component so as to produce a signal indicating a temperature of the tissue.
3. The therapeutic heating device of
claim 2
, wherein the component comprises a transistor, thermistor or diode.
4. The therapeutic heating device of
claim 2
, wherein the power source produces a second power, the second power being less than the first power and sufficient to produce the temperature signal.
5. The therapeutic heating device of
claim 4
, wherein the power source alternates between the first and second power in a heating/sensing cycle such that the temperature signal indicates the temperature of the target tissue.
6. The therapeutic heating device of
claim 5
, further comprising a processor coupled to the temperature circuitry, wherein the processor varies the heating/sensing cycle depending on the temperature signal.
7. The therapeutic heating device of
claim 2
, further comprising a heat limiting mechanism coupled to the conductor, wherein the heat limiting mechanism limits application of the first power to the electrode so that the target tissue does not rise above a tissue contraction temperature within a range from about 70° C. to about 140° C.
8. A tissue contraction system comprising:
a heat transfer surface oriented for engaging a tissue surface of a tissue;
an electrical component thermally coupled to the heat transfer surface; and
an electrical power supply system electrically coupled to the component, the power supply directing electrical energy to the component, the energy heating the component so that the component heats the tissue to a temperature within a tissue contraction temperature range by thermal conduction of heat energy from the component, through the heat transfer surface, and to the tissue surface.
9. A method for contracting tissue, the method comprising:
engaging a heat transfer surface against the tissue;
heating the tissue with the heat transfer surface by heating an electrical component thermally coupled to the heat transfer surface; and
controlling the heating step using an electrical signal from the component so that the tissue contracts without ablating the tissue.
US09/170,765 1998-07-31 1998-10-13 Temperature sensing devices and methods to shrink tissues Expired - Lifetime US6322584B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/170,765 US6322584B2 (en) 1998-07-31 1998-10-13 Temperature sensing devices and methods to shrink tissues
AU51225/99A AU5122599A (en) 1998-07-31 1999-07-22 Temperature sensing devices and methods to shrink tissues
PCT/US1999/016597 WO2000006061A1 (en) 1998-07-31 1999-07-22 Temperature sensing devices and methods to shrink tissues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9494698P 1998-07-31 1998-07-31
US09/170,765 US6322584B2 (en) 1998-07-31 1998-10-13 Temperature sensing devices and methods to shrink tissues

Publications (2)

Publication Number Publication Date
US20010018601A1 true US20010018601A1 (en) 2001-08-30
US6322584B2 US6322584B2 (en) 2001-11-27

Family

ID=26789370

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/170,765 Expired - Lifetime US6322584B2 (en) 1998-07-31 1998-10-13 Temperature sensing devices and methods to shrink tissues

Country Status (3)

Country Link
US (1) US6322584B2 (en)
AU (1) AU5122599A (en)
WO (1) WO2000006061A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080125771A1 (en) * 2006-11-27 2008-05-29 Michael Lau Methods and apparatuses for contouring tissue by selective application of energy
US20140094786A1 (en) * 2012-10-02 2014-04-03 Covidien Lp Medical devices for thermally treating tissue
US20160331459A1 (en) * 2015-05-12 2016-11-17 National University Of Ireland, Galway Devices for therapeutic nasal neuromodulation and associated methods and systems
CN108042200A (en) * 2017-12-19 2018-05-18 上海置信节能环保有限公司 A kind of cooling system for medical frozen knife
US10806921B2 (en) 2016-11-11 2020-10-20 National University Of Ireland, Galway Devices, systems, and methods for specializing, monitoring, and/or evaluating therapeutic nasal neuromodulation

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115123B2 (en) * 1996-01-05 2006-10-03 Thermage, Inc. Handpiece with electrode and non-volatile memory
US7317949B2 (en) * 1996-11-08 2008-01-08 Ams Research Corporation Energy induced bulking and buttressing of tissues for incontinence
US6292700B1 (en) * 1999-09-10 2001-09-18 Surx, Inc. Endopelvic fascia treatment for incontinence
US6634363B1 (en) 1997-04-07 2003-10-21 Broncus Technologies, Inc. Methods of treating lungs having reversible obstructive pulmonary disease
US7992572B2 (en) 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
US7027869B2 (en) 1998-01-07 2006-04-11 Asthmatx, Inc. Method for treating an asthma attack
US6104959A (en) 1997-07-31 2000-08-15 Microwave Medical Corp. Method and apparatus for treating subcutaneous histological features
US9023031B2 (en) 1997-08-13 2015-05-05 Verathon Inc. Noninvasive devices, methods, and systems for modifying tissues
CA2300152A1 (en) * 1997-08-13 1999-02-25 Surx, Inc. Noninvasive devices, methods, and systems for shrinking of tissues
US7921855B2 (en) 1998-01-07 2011-04-12 Asthmatx, Inc. Method for treating an asthma attack
WO1999035983A1 (en) 1998-01-14 1999-07-22 Surx, Inc. Ribbed electrodes and methods for their use
US8181656B2 (en) 1998-06-10 2012-05-22 Asthmatx, Inc. Methods for treating airways
US7198635B2 (en) 2000-10-17 2007-04-03 Asthmatx, Inc. Modification of airways by application of energy
US6589235B2 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Method and apparatus for cartilage reshaping by radiofrequency heating
US8251070B2 (en) 2000-03-27 2012-08-28 Asthmatx, Inc. Methods for treating airways
US7306591B2 (en) 2000-10-02 2007-12-11 Novasys Medical, Inc. Apparatus and methods for treating female urinary incontinence
US6673063B2 (en) * 2000-10-06 2004-01-06 Expanding Concepts, Llc. Epidural thermal posterior annuloplasty
US7104987B2 (en) 2000-10-17 2006-09-12 Asthmatx, Inc. Control system and process for application of energy to airway walls and other mediums
US6607525B2 (en) * 2001-08-01 2003-08-19 Nicolas Franco Apparatus and method for treating urinary stress incontinence
US6882885B2 (en) * 2002-03-19 2005-04-19 Solarant Medical, Inc. Heating method for tissue contraction
JP2005535370A (en) 2002-06-19 2005-11-24 パロマー・メディカル・テクノロジーズ・インコーポレイテッド Method and apparatus for treating skin and subcutaneous conditions
US6852110B2 (en) * 2002-08-01 2005-02-08 Solarant Medical, Inc. Needle deployment for temperature sensing from an electrode
EP2604216B1 (en) 2003-02-25 2018-08-22 Tria Beauty, Inc. Self-contained, diode-laser-based dermatologic treatment apparatus
ES2570987T3 (en) 2003-02-25 2016-05-23 Tria Beauty Inc Dermatological treatment device, based on diode laser and autonomous
US7981111B2 (en) * 2003-02-25 2011-07-19 Tria Beauty, Inc. Method and apparatus for the treatment of benign pigmented lesions
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7476242B2 (en) * 2004-01-30 2009-01-13 Ams Research Corporation Electrically heated/phase change probe temperature control
US7251531B2 (en) * 2004-01-30 2007-07-31 Ams Research Corporation Heating method for tissue contraction
US20060009749A1 (en) * 2004-02-19 2006-01-12 Weckwerth Mark V Efficient diffuse light source assembly and method
US8777935B2 (en) 2004-02-25 2014-07-15 Tria Beauty, Inc. Optical sensor and method for identifying the presence of skin
JP4624697B2 (en) * 2004-03-12 2011-02-02 オリンパス株式会社 Surgical instrument
US20050283147A1 (en) * 2004-06-17 2005-12-22 Chie Yachi Surgical treatment device and surgical treatment system
US7949407B2 (en) 2004-11-05 2011-05-24 Asthmatx, Inc. Energy delivery devices and methods
WO2006052940A2 (en) 2004-11-05 2006-05-18 Asthmatx, Inc. Medical device with procedure improvement features
US20070093802A1 (en) 2005-10-21 2007-04-26 Danek Christopher J Energy delivery devices and methods
JP4143114B2 (en) * 2005-03-02 2008-09-03 メリディアン カンパニー リミテッド Lipolysis device using low power laser
US7856985B2 (en) 2005-04-22 2010-12-28 Cynosure, Inc. Method of treatment body tissue using a non-uniform laser beam
US20070005049A1 (en) * 2005-06-30 2007-01-04 Comben Richard H Apparatus and Method of Treating Urinary Incontinence by Heating Urethra
US8721634B2 (en) 2005-07-21 2014-05-13 Covidien Lp Apparatus and method for ensuring thermal treatment of a hollow anatomical structure
WO2007092610A2 (en) * 2006-02-07 2007-08-16 Tivamed, Inc. Vaginal remodeling device and methods
US7586957B2 (en) 2006-08-02 2009-09-08 Cynosure, Inc Picosecond laser apparatus and methods for its operation and use
US7931647B2 (en) 2006-10-20 2011-04-26 Asthmatx, Inc. Method of delivering energy to a lung airway using markers
US7766907B2 (en) * 2006-12-28 2010-08-03 St. Jude Medical, Atrial Fibrillation Division, Inc. Ablation catheter with sensor array and discrimination circuit to minimize variation in power density
WO2009075903A1 (en) 2007-04-19 2009-06-18 The Foundry, Inc. Systems and methods for creating an effect using microwave energy to specified tissue
US20100211059A1 (en) 2007-04-19 2010-08-19 Deem Mark E Systems and methods for creating an effect using microwave energy to specified tissue
EP2767308B1 (en) 2007-04-19 2016-04-13 Miramar Labs, Inc. Devices, and systems for non-invasive delivery of microwave therapy
US9149331B2 (en) 2007-04-19 2015-10-06 Miramar Labs, Inc. Methods and apparatus for reducing sweat production
US20090018531A1 (en) * 2007-06-08 2009-01-15 Cynosure, Inc. Coaxial suction system for laser lipolysis
US8235983B2 (en) 2007-07-12 2012-08-07 Asthmatx, Inc. Systems and methods for delivering energy to passageways in a patient
EP2194899A4 (en) 2007-08-08 2012-11-28 Tria Beauty Inc Capacitive sensing method and device for detecting skin
US20090149930A1 (en) * 2007-12-07 2009-06-11 Thermage, Inc. Apparatus and methods for cooling a treatment apparatus configured to non-invasively deliver electromagnetic energy to a patient's tissue
AU2008335715B2 (en) 2007-12-12 2014-01-23 Miradry, Inc. Systems, apparatus, methods and procedures for the noninvasive treatment of tissue using microwave energy
BRPI0820706B8 (en) 2007-12-12 2021-06-22 Miramar Labs Inc disposable medical device for use with an applicator
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
EP2271276A4 (en) 2008-04-17 2013-01-23 Miramar Labs Inc Systems, apparatus, methods and procedures for the noninvasive treatment of tissue using microwave energy
US9687671B2 (en) 2008-04-25 2017-06-27 Channel Investments, Llc Optical sensor and method for identifying the presence of skin and the pigmentation of skin
US8515553B2 (en) * 2008-04-28 2013-08-20 Thermage, Inc. Methods and apparatus for predictively controlling the temperature of a coolant delivered to a treatment device
AU2009244058B2 (en) 2008-05-09 2015-07-02 Nuvaira, Inc Systems, assemblies, and methods for treating a bronchial tree
US8192427B2 (en) 2008-06-09 2012-06-05 Tyco Healthcare Group Lp Surface ablation process with electrode cooling methods
US8285392B2 (en) * 2008-06-19 2012-10-09 Thermage, Inc. Leakage-resistant tissue treatment apparatus and methods of using such tissue treatment apparatus
US8121704B2 (en) * 2008-06-19 2012-02-21 Thermage, Inc. Leakage-resistant tissue treatment apparatus and methods of using same
CA2774265C (en) 2009-09-18 2019-02-19 Viveve, Inc. Vaginal remodeling device and methods
WO2011056684A2 (en) 2009-10-27 2011-05-12 Innovative Pulmonary Solutions, Inc. Delivery devices with coolable energy emitting assemblies
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9314301B2 (en) 2011-08-01 2016-04-19 Miramar Labs, Inc. Applicator and tissue interface module for dermatological device
US9468493B2 (en) 2012-01-04 2016-10-18 Covidien Lp Apparatus, system, and method for performing surface tissue desiccation having an internal cooling system
US10076383B2 (en) 2012-01-25 2018-09-18 Covidien Lp Electrosurgical device having a multiplexer
WO2013123089A1 (en) * 2012-02-17 2013-08-22 Cohen Nathaniel L Apparatus for using microwave energy for insect and pest control and methods thereof
CN105919666A (en) 2012-03-16 2016-09-07 女康乐公司 Therapy equipment for repairing female vaginal tissue
US8403927B1 (en) 2012-04-05 2013-03-26 William Bruce Shingleton Vasectomy devices and methods
KR102183581B1 (en) 2012-04-18 2020-11-27 싸이노슈어, 엘엘씨 Picosecond laser apparatus and methods for treating target tissues with same
US9770293B2 (en) 2012-06-04 2017-09-26 Boston Scientific Scimed, Inc. Systems and methods for treating tissue of a passageway within a body
WO2014018153A1 (en) 2012-07-24 2014-01-30 Boston Scientific Scimed, Inc. Electrodes for tissue treatment
US9993658B2 (en) 2012-08-16 2018-06-12 Yolo Medical Inc. Light applicators, systems and methods
US9272132B2 (en) 2012-11-02 2016-03-01 Boston Scientific Scimed, Inc. Medical device for treating airways and related methods of use
US9283374B2 (en) 2012-11-05 2016-03-15 Boston Scientific Scimed, Inc. Devices and methods for delivering energy to body lumens
US9204921B2 (en) 2012-12-13 2015-12-08 Cook Medical Technologies Llc RF energy controller and method for electrosurgical medical devices
US9364277B2 (en) 2012-12-13 2016-06-14 Cook Medical Technologies Llc RF energy controller and method for electrosurgical medical devices
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
EP2973894A2 (en) 2013-03-15 2016-01-20 Cynosure, Inc. Picosecond optical radiation systems and methods of use
US9814618B2 (en) 2013-06-06 2017-11-14 Boston Scientific Scimed, Inc. Devices for delivering energy and related methods of use
WO2015013502A2 (en) 2013-07-24 2015-01-29 Miramar Labs, Inc. Apparatus and methods for the treatment of tissue using microwave energy
EP3335658B1 (en) 2013-08-09 2020-04-22 Boston Scientific Scimed, Inc. Expandable catheter
EP3209236B1 (en) 2015-03-31 2020-06-10 St. Jude Medical, Cardiology Division, Inc. Device for delivering pulsed rf energy during catheter ablation
EP3522809B1 (en) 2016-10-04 2021-11-24 St. Jude Medical, Cardiology Division, Inc. Ablation catheter tip
US11896823B2 (en) 2017-04-04 2024-02-13 Btl Healthcare Technologies A.S. Method and device for pelvic floor tissue treatment
WO2019165426A1 (en) 2018-02-26 2019-08-29 Cynosure, Inc. Q-switched cavity dumped sub-nanosecond laser
AU2019204574A1 (en) 2018-06-27 2020-01-23 Viveve, Inc. Methods for treating urinary stress incontinence

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4453536A (en) 1980-11-03 1984-06-12 Abild Robert N Body channel occluder
US5370675A (en) 1992-08-12 1994-12-06 Vidamed, Inc. Medical probe device and method
JPS61128958A (en) * 1984-11-28 1986-06-17 オリンパス光学工業株式会社 Cauterization hemostatic apparatus
US4679561A (en) 1985-05-20 1987-07-14 The United States Of America As Represented By The United States Department Of Energy Implantable apparatus for localized heating of tissue
US4654024A (en) * 1985-09-04 1987-03-31 C.R. Bard, Inc. Thermorecanalization catheter and method for use
US4802479A (en) 1986-10-31 1989-02-07 C. R. Bard, Inc. Hand-held instrument for implanting, dispensing, and inflating an inflatable membrane
US4765331A (en) 1987-02-10 1988-08-23 Circon Corporation Electrosurgical device with treatment arc of less than 360 degrees
US5246440A (en) * 1990-09-13 1993-09-21 Noord Andrew J Van Electrosurgical knife
US5370671A (en) 1991-03-26 1994-12-06 Empi, Inc. Incontinence electrode apparatus
US5199443A (en) 1991-03-26 1993-04-06 Empi, Inc. Incontinence electrode apparatus
US5190517A (en) 1991-06-06 1993-03-02 Valleylab Inc. Electrosurgical and ultrasonic surgical system
US5697909A (en) 1992-01-07 1997-12-16 Arthrocare Corporation Methods and apparatus for surgical cutting
US5697882A (en) 1992-01-07 1997-12-16 Arthrocare Corporation System and method for electrosurgical cutting and ablation
US5314466A (en) 1992-04-13 1994-05-24 Ep Technologies, Inc. Articulated unidirectional microwave antenna systems for cardiac ablation
US5281217A (en) 1992-04-13 1994-01-25 Ep Technologies, Inc. Steerable antenna systems for cardiac ablation that minimize tissue damage and blood coagulation due to conductive heating patterns
US5293869A (en) 1992-09-25 1994-03-15 Ep Technologies, Inc. Cardiac probe with dynamic support for maintaining constant surface contact during heart systole and diastole
US5348554A (en) 1992-12-01 1994-09-20 Cardiac Pathways Corporation Catheter for RF ablation with cooled electrode
US5533999A (en) 1993-08-23 1996-07-09 Refractec, Inc. Method and apparatus for modifications of visual acuity by thermal means
US5496312A (en) 1993-10-07 1996-03-05 Valleylab Inc. Impedance and temperature generator control
US5536267A (en) 1993-11-08 1996-07-16 Zomed International Multiple electrode ablation apparatus
CA2181453A1 (en) 1994-01-18 1995-07-20 George F. Kick Apparatus and method for venous ligation
US5437664A (en) 1994-01-18 1995-08-01 Endovascular, Inc. Apparatus and method for venous ligation
US5458596A (en) 1994-05-06 1995-10-17 Dorsal Orthopedic Corporation Method and apparatus for controlled contraction of soft tissue
US5810802A (en) * 1994-08-08 1998-09-22 E.P. Technologies, Inc. Systems and methods for controlling tissue ablation using multiple temperature sensing elements
US5514130A (en) 1994-10-11 1996-05-07 Dorsal Med International RF apparatus for controlled depth ablation of soft tissue
US5588960A (en) 1994-12-01 1996-12-31 Vidamed, Inc. Transurethral needle delivery device with cystoscope and method for treatment of urinary incontinence
US5660836A (en) 1995-05-05 1997-08-26 Knowlton; Edward W. Method and apparatus for controlled contraction of collagen tissue
US5837001A (en) 1995-12-08 1998-11-17 C. R. Bard Radio frequency energy delivery system for multipolar electrode catheters
US5769880A (en) 1996-04-12 1998-06-23 Novacept Moisture transport system for contact electrocoagulation
WO1997043971A2 (en) 1996-05-22 1997-11-27 Somnus Medical Technologies, Inc. Method and apparatus for ablating turbinates
US5893885A (en) * 1996-11-01 1999-04-13 Cordis Webster, Inc. Multi-electrode ablation catheter
US5830211A (en) 1997-03-10 1998-11-03 Santana; Jose A. Probe to treat viral lesions

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080125771A1 (en) * 2006-11-27 2008-05-29 Michael Lau Methods and apparatuses for contouring tissue by selective application of energy
US20140094786A1 (en) * 2012-10-02 2014-04-03 Covidien Lp Medical devices for thermally treating tissue
US9439711B2 (en) * 2012-10-02 2016-09-13 Covidien Lp Medical devices for thermally treating tissue
EP2716250A3 (en) * 2012-10-02 2017-05-03 Covidien LP Medical devices for thermally treating tissue
US10154872B2 (en) 2012-10-02 2018-12-18 Covidien Lp Medical devices for thermally treating tissue
US20160331459A1 (en) * 2015-05-12 2016-11-17 National University Of Ireland, Galway Devices for therapeutic nasal neuromodulation and associated methods and systems
US10806921B2 (en) 2016-11-11 2020-10-20 National University Of Ireland, Galway Devices, systems, and methods for specializing, monitoring, and/or evaluating therapeutic nasal neuromodulation
CN108042200A (en) * 2017-12-19 2018-05-18 上海置信节能环保有限公司 A kind of cooling system for medical frozen knife

Also Published As

Publication number Publication date
US6322584B2 (en) 2001-11-27
WO2000006061A1 (en) 2000-02-10
AU5122599A (en) 2000-02-21

Similar Documents

Publication Publication Date Title
US6322584B2 (en) Temperature sensing devices and methods to shrink tissues
US6572639B1 (en) Interspersed heating/cooling to shrink tissues for incontinence
US6139569A (en) Interspersed heating/cooling to shrink tissues for incontinence
US6156060A (en) Static devices and methods to shrink tissues for incontinence
US6236891B1 (en) Limited heat transfer devices and methods to shrink tissues
US6533780B1 (en) Ribbed electrodes and methods for their use
US6480746B1 (en) Noninvasive devices, methods, and systems for shrinking of tissues
US6035238A (en) Noninvasive devices, methods, and systems for shrinking of tissues
US6081749A (en) Noninvasive devices, methods, and systems for shrinking of tissues
AU755674B2 (en) Static devices and methods to shrink tissues for incontinence
US6546934B1 (en) Noninvasive devices and methods for shrinking of tissues
US9023031B2 (en) Noninvasive devices, methods, and systems for modifying tissues
WO2000006035A1 (en) Limited heat transfer devices and methods to shrink tissues

Legal Events

Date Code Title Description
AS Assignment

Owner name: SURX, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:INGLE, FRANK W.;ROY, LOREN L.;REEL/FRAME:009637/0526

Effective date: 19981119

AS Assignment

Owner name: COMDISCO, INC., ILLINOIS

Free format text: SECURITY INTEREST;ASSIGNOR:SURX, INC.;REEL/FRAME:010170/0212

Effective date: 19990809

Owner name: MMC/GATX PARTNERSHIP NO.1, CALIFORNIA

Free format text: SECURITY INTEREST;ASSIGNOR:SURX, INC.;REEL/FRAME:010170/0212

Effective date: 19990809

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: MMC/GATX PARTNERSHIP NO. I, CALIFORNIA

Free format text: RELEASE OF SECURITY INTEREST FILED ON 8/16/99;ASSIGNOR:SURX, INC.;REEL/FRAME:012675/0262

Effective date: 19990809

AS Assignment

Owner name: SURX, INC., CALIFORNIA

Free format text: TERMINATION SECURITY INTEREST IN PATENTS;ASSIGNORS:MMC/GATX PARTNERSHIP NO. I;COMDISCO, INC.;REEL/FRAME:014137/0642

Effective date: 20010411

AS Assignment

Owner name: SOLARANT MEDICAL, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:SURX, INC.;REEL/FRAME:014523/0207

Effective date: 20040203

FEPP Fee payment procedure

Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: AMS RESEARCH CORPORATION, MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOLARANT MEDICAL, INC.;REEL/FRAME:018087/0904

Effective date: 20060605

AS Assignment

Owner name: CIT HEALTHCARE LLC, NEW YORK

Free format text: SECURITY AGREEMENT;ASSIGNOR:SOLARANT MEDICAL, INC.;REEL/FRAME:018120/0843

Effective date: 20060720

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: SOLARANT MEDICAL, INC., MINNESOTA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CIT HEALTHCARE LLC;REEL/FRAME:026142/0160

Effective date: 20110412

AS Assignment

Owner name: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRA

Free format text: SECURITY AGREEMENT;ASSIGNOR:AMS RESEARCH CORPORATION;REEL/FRAME:026632/0535

Effective date: 20110617

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: AMS RESEARCH CORPORATION, MINNESOTA

Free format text: RELEASE OF PATENT SECURITY INTEREST;ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT;REEL/FRAME:032380/0053

Effective date: 20140228

AS Assignment

Owner name: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT, NEW YORK

Free format text: GRANT OF SECURITY INTEREST IN PATENTS;ASSIGNORS:ENDO PHARMACEUTICALS SOLUTIONS, INC.;ENDO PHARMACEUTICALS, INC.;AMS RESEARCH CORPORATION;AND OTHERS;REEL/FRAME:032491/0440

Effective date: 20140228

Owner name: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AG

Free format text: GRANT OF SECURITY INTEREST IN PATENTS;ASSIGNORS:ENDO PHARMACEUTICALS SOLUTIONS, INC.;ENDO PHARMACEUTICALS, INC.;AMS RESEARCH CORPORATION;AND OTHERS;REEL/FRAME:032491/0440

Effective date: 20140228

AS Assignment

Owner name: AMERICAN MEDICAL SYSTEMS, LLC, MINNESOTA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH;REEL/FRAME:036285/0146

Effective date: 20150803

Owner name: AMS RESEARCH, LLC, MINNESOTA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH;REEL/FRAME:036285/0146

Effective date: 20150803

Owner name: LASERSCOPE, CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH;REEL/FRAME:036285/0146

Effective date: 20150803

AS Assignment

Owner name: AMS RESEARCH, LLC, MINNESOTA

Free format text: CHANGE OF NAME;ASSIGNOR:AMS RESEARCH CORPATION;REEL/FRAME:037300/0318

Effective date: 20141217

AS Assignment

Owner name: APHRODITE WOMEN'S HEALTH, LLC, MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AMS RESEARCH, LLC;REEL/FRAME:037473/0260

Effective date: 20150227

Owner name: ASTORA WOMEN'S HEALTH, LLC, MINNESOTA

Free format text: CHANGE OF NAME;ASSIGNOR:APHRODITE WOMEN'S HEALTH, LLC;REEL/FRAME:037473/0354

Effective date: 20150929

AS Assignment

Owner name: AMS RESEARCH, LLC, MINNESOTA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED AT REEL: 037300 FRAME: 0318. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME;ASSIGNOR:AMS RESEARCH CORPORATION;REEL/FRAME:039919/0017

Effective date: 20141217

AS Assignment

Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE, DELAWARE

Free format text: SECURITY INTEREST;ASSIGNOR:ASTORA WOMEN'S HEALTH, LLC;REEL/FRAME:042743/0278

Effective date: 20170427

Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATE

Free format text: SECURITY INTEREST;ASSIGNOR:ASTORA WOMEN'S HEALTH, LLC;REEL/FRAME:042743/0278

Effective date: 20170427

AS Assignment

Owner name: VINTAGE PHARMACEUTICALS, LLC, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: SLATE PHARMACEUTICALS, LLC, PENNSYLVANIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: QUARTZ SPECIALTY PHARMACEUTICALS, LLC, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC), NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: PAR PHARMACEUTICAL, INC., NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: GENERICS INTERNATIONAL (US), INC., NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: GENERICS BIDCO I, LLC, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.), PENNSYLVANIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: ENDO PHARMACEUTICALS INC., PENNSYLVANIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.), PENNSYLVANIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: DAVA PHARMACEUTICALS, LLC, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: DAVA INTERNATIONAL, LLC, PENNSYLVANIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: BIOSPECIFICS TECHNOLOGIES LLC, PENNSYLVANIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: BIOSPECIFICS TECHNOLOGIES CORP., PENNSYLVANIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: AUXILIUM US HOLDINGS, LLC, PENNSYLVANIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: AUXILIUM PHARMACEUTICALS, LLC, PENNSYLVANIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: ASTORA WOMEN'S HEALTH LLC, PENNSYLVANIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: ASTORA WOMEN'S HEALTH HOLDINGS, LLC, MINNESOTA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423

Owner name: ACTIENT PHARMACEUTICALS LLC, PENNSYLVANIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION;REEL/FRAME:067240/0001

Effective date: 20240423